

1 **ATRIP deficiency impairs the replication stress response and manifests as** 2 **microcephalic primordial dwarfism and immunodeficiency.**

3 **Authors:** Evi Duthoo^{1,2,3,†}, Elien Beyls^{1,2,3,†}, Lynn Backers^{1,4,5,†}, Thorkell Gudjónsson⁶, Peiquan Huang⁶,
4 Leander Jonckheere^{7,8}, Sebastian Riemann^{8,9}, Bram Parton^{4,5}, Likun Du¹⁰, Veronique Debacker^{1,2},
5 Marieke De Bruyne^{4,5}, Levi Hoste^{1,11}, Ans Baeyens¹², Anne Vral¹², Eva Van Braeckel^{7,8}, Jens Staal^{13,14},
6 Geert Mortier¹⁵, Tessa Kerre^{2,16}, Qiang Pan-Hammarström¹⁰, Claus Storgaard Sørensen⁶, Filomeen
7 Haerynck^{1,2,17,†*}, Kathleen BM Claes^{4,5,†*}, Simon J Tavernier^{1,2,4,13,14,†}

8 † These authors contributed equally to this work, ‡ These authors share last authorship, * Corresponding authors

9 ¹Primary Immunodeficiency Research Lab (PIRL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent,
10 Belgium.

11 ²Center for Primary Immunodeficiency, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent,
12 Belgium.

13 ³Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

14 ⁴Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

15 ⁵Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

16 ⁶Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen,
17 Denmark.

18 ⁷Respiratory Infection and Defense Lab (RIDL), Department of Internal Medicine and Pediatrics, Ghent University, Ghent,
19 Belgium.

20 ⁸Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.

21 ⁹Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Internal Medicine and Pediatrics,
22 Ghent University, Ghent, Belgium.

23 ¹⁰Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

24 ¹¹Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.

25 ¹²Radiobiology Lab, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

26 ¹³Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.

27 ¹⁴Unit of Molecular Signal Transduction in Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium.

28 ¹⁵Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium.

29 ¹⁶Department of Hematology, Ghent University Hospital, Ghent, Belgium.

30 ¹⁷Department of Pediatric Respiratory and Infectious Medicine, Ghent University Hospital, Ghent, Belgium.

31

32 **Correspondence:**

33 Email: Filomeen.Haerynck@ugent.be, Kathleen.Claes@ugent.be

34 **ABSTRACT**

35 ATR (Ataxia Telangiectasia and Rad3-related) kinase and its interacting protein ATRIP orchestrate the
36 replication stress response. Two patients of independent ancestry with microcephaly, primordial
37 dwarfism, and recurring infections were found to be homozygous for splice donor site variants of *ATRIP*
38 exon 5, resulting in ATRIP deficiency. The c.829+5G>T patient exhibited autoimmune hemolytic
39 anemia, lymphopenia, poor vaccine response, and intermittent neutropenia. Immunophenotyping
40 revealed reduced CD16⁺ NK cells and absent naïve T cells, mucosal-associated invariant T cells
41 (MAITs), and invariant natural killer T cells (iNKTs). Lymphocytic defects were characterized by T cell
42 receptor (TCR) oligoclonality, abnormal class switch recombination (CSR), and impaired T cell
43 proliferation. ATRIP deficiency resulted in low-grade ATR activation but impaired CHK1
44 phosphorylation upon genotoxic stress. Consequently, ATRIP deficient cells inadequately regulated
45 DNA replication, leading to chromosomal instability, compromised cell cycle control, and impaired cell
46 viability. CRISPR-Select^{TIME} confirmed reduced cell fitness induced by both variants. This study
47 establishes ATRIP deficiency as a monogenic cause of microcephalic primordial dwarfism, highlights
48 ATRIP's critical role in protecting immune cells from replication stress, and brings a renewed
49 perspective to the canonical functions of ATRIP.

50 INTRODUCTION

51 Maintaining genomic integrity requires cells to deploy defense mechanisms to counteract various DNA-
52 damaging assaults. The phosphatidylinositol 3-kinase-related kinases (PIKKs) ATR, ATM, and DNA-
53 PKcs act as key mediators of the DNA damage response (DDR), initiating signaling cascades that
54 coordinate cell cycle progression, checkpoint activation, and concurrent DNA repair^{1,2}. While ATM and
55 DNA-PKcs respond to DNA double-strand breaks (DSBs), ATR primarily safeguards DNA synthesis
56 during the S phase^{2,3}. RPA-coated single-stranded DNA (ssDNA) arises after processing of damaged
57 DNA, including stalled replication forks, resected DSBs, and UV-induced bulky adducts, and serves as
58 a platform for ATR activation. By phosphorylating substrates such as CHK1, ATR orchestrates the
59 replication stress response, triggering intra-S and G2/M checkpoints, suppressing origin firing,
60 stabilizing replication forks, and promoting replication fork restart⁴⁻⁶. ATR is essential for mammalian
61 DNA replication and complete loss of ATR was shown to result in early embryonic lethality in mice⁷⁻
62 ¹¹. A homozygous hypomorphic leaky splice variant in *ATR* (NM_001184.4 (*ATR*): c.2022A>G,
63 p.(Gly674=)) was first reported by O'Driscoll et al.¹² in two families with Seckel Syndrome¹³ (OMIM
64 210600), a form of microcephalic primordial dwarfism (MPD) associated with intellectual disability and
65 distinct craniofacial features. To date, four additional *ATR* patients have been described, all harboring
66 biallelic hypomorphic variants, leading to highly diminished but not abolished ATR protein levels¹⁴⁻¹⁶.

67
68 The ubiquitously expressed ATR-interacting protein (ATRIP) is an essential binding partner of ATR,
69 illustrated by the co-dependency of ATRIP and ATR for protein stability¹¹. On a functional level, ATRIP
70 recognizes and binds RPA-ssDNA nucleoprotein filaments, allowing ATR recruitment and subsequent
71 activation by the kinases TOPBP1 and the recently identified ETAA1¹⁷. The structural basis for this
72 signaling nexus has recently been resolved: the N-terminal RPA-binding motif of ATRIP directly
73 interacts with RPA while its coiled-coil domain is required for the simultaneous homodimerization of
74 two ATRIP molecules. Through its C-terminal HEAT motifs, ATRIP associates with the N-terminal
75 region of ATR and these ATR-ATRIP complexes form stable dimers of heterodimers upon recruitment
76 to RPA-ssDNA¹⁸⁻²⁰. Mutational analyses revealed that ATRIP-TOPBP1 interactions and downstream
77 ATR activation depend on a region adjacent to the coiled-coil domain in ATRIP²⁰. Unlike TOPBP1,
78 which relies on both ATRIP and the RAD9–RAD1–HUS1 (9-1-1) clamp for recruitment to the ATRIP-
79 ATR complex, ETAA1 directly interacts with RPA-ssDNA and ATR^{17,21,22}. Defective ATRIP function
80 is associated with human disease as reduced ATRIP expression was found in a patient with MPD¹⁴ and
81 heterozygous *ATRIP* loss-of-function variants have been associated with breast cancer susceptibility²³.
82 Moreover, conditional ATRIP loss in the central nervous system in mice resulted in microcephaly,
83 providing further evidence for a causal link between ATRIP deficiency and MPD²⁴.

84
85 MPDs are a genetically heterogeneous group of overlapping disorders, defined by severe microcephaly
86 and intrauterine and postnatal growth restriction. Pathogenic variants associated with MPDs have been
87 identified in genes involved in seemingly distinct cellular processes such as DNA replication initiation,
88 DNA repair, cell cycle progression, and centrosome function²⁵⁻²⁸. Disruption of the encoded proteins
89 consistently restrict cell proliferation dynamics, thus exposing the common biological basis of MPDs.
90 In addition, several of the genes involved in DNA replication initiation (*MCM4*, *MCM10*, *GINS1*,
91 *GINS4*, *POLD1-2*, *POLE1-2*), when disrupted, give rise to a syndromic combined immunodeficiency
92 (CID). Although clinically variable, these immunodeficiencies have in common that they are
93 characterized by susceptibility to severe infections by herpes viruses and defects in the natural killer
94 (NK) cell compartment²⁹⁻³⁷.

95

96 Here, we report that ATRIP deficiency, caused by homozygous splice variants in *ATRIP*, manifests with
97 features of MPD and immunodeficiency. The loss-of-function (LOF) *ATRIP* variants allow residual
98 ATR activity, although profoundly impaired. We performed a comprehensive analysis of the functional
99 impact of ATRIP loss on ATR signaling activity and delineated the accompanying downstream cellular
100 outcomes. In addition to genomic instability, patient-derived cells display an inadequate ATR response
101 to genotoxic lesions, as evidenced by dysregulated cell cycle progression, increased chromosomal
102 sensitivity, impaired proliferation, and pronounced decline in cell viability. Modeling of the *ATRIP*
103 variants by CRISPR-Select^{TIME} revealed reduced cell fitness³⁸. Our observations highlight a more
104 nuanced role of ATRIP within the ATR signaling pathway, clarify the biological basis of ATRIP-
105 mediated human disease, and expand the disease phenotype associated with ATRIP deficiency.

106 RESULTS

107 *Personally identifiable patient information was redacted in accordance with medRxiv requirements.*

108 **Homozygous intronic *ATRIP* variants in patients with MPD and immunodeficiency**

109 F1Pt was born at term, small for gestational age, and presented with severe microcephaly, developmental
110 delay, and dysmorphic features (Supplementary Fig. 1a, b). Clinical investigations revealed failure to
111 thrive, growth retardation, grossly normal skeletal development, and a mild intellectual disability (ID).
112 Between the ages of 0-5, she developed severe varicella and recurring respiratory tract infections (RTIs).
113 Laboratory investigations showed lymphopenia and intermittent neutropenia (Table 1). Whole exome
114 sequencing (WES) revealed a homozygous splice variant in intron 5 of the *ATRIP* gene (NM_13038.3):
115 c.829+5G>T (Chr3(GRCh38):g.48457421G>T), which was confirmed by Sanger sequencing (Fig. 1a
116 and Supplementary Fig. 1c). Importantly, WES analysis of a large cohort of patients with microcephaly
117 identified a male patient of North Indian ancestry (patient F46.1) with another homozygous splice
118 variant in intron 5 of *ATRIP* (c.829+2T>G)³⁹. He presented with similar phenotypic features of facial
119 dysmorphism, short stature, microcephaly, moderate ID, and recurrent RTIs (Supplementary Fig. 1a).
120 Finally, microcephaly and short stature has already been reported in a patient with reduced *ATRIP*
121 expression, due to defective splicing (patient CV1720)¹⁴. Reappraisal of patient CV1720's clinical status
122 revealed a similar phenotype of late-onset lymphopenia and intermittent neutropenia (Table 1). More
123 detailed clinical information can be found in the case descriptions (Supplementary Materials and
124 Supplementary Table 1).

125 *In silico* tools predicted inactivation of the wild-type splice donor site near exon 5 for both variants
126 (Supplementary Table 2). Analysis of the population database gnomAD v4.0.0 revealed absence of the
127 c.829+2T>G variant and presence of only five alleles of the c.829+5G>T variant, exclusively in a
128 heterozygous state in the European (non-Finnish) subpopulation (MAF: 0.0004369%). Eleven
129 homozygous variants in *ATRIP* splice boundaries, identified in gnomAD v4.0.0 (Supplementary Table
130 3), were present with high allele frequencies (0.0001368% - 56.0807635%) and showed exclusively low
131 recall cutoff SpliceAI scores (recall cutoff <0.2; 0.00 - 0.18) (Supplementary Fig. 1d). Eight of the
132 eleven homozygous variants were classified as benign (6/8) or likely benign (2/8) in ClinVar
133 (Supplementary Table 3). Based on the clinical and genetic evidence presented above, *ATRIP* was
134 considered a plausible candidate gene for MPD and immunodeficiency.

135 ***ATRIP* c.829+5G>T results in skipping of exon 5**

136 To investigate the effect at the transcriptional level, reverse transcription PCR (RT-PCR) and Sanger
137 sequencing was performed in PHA blasts (Fig. 1b, c) and fibroblasts (Supplementary Fig. 1e) from F1Pt.
138 This failed to reveal a full-length transcript, but instead, showed presence of a transcript lacking exon 5
139 (Δ ex5, r.671_829del; p.(Ser224ArgfsTer2)) (Fig. 1d). In PHA blasts from her parents (F1Mo and F1Fa),
140 both the full-length and the shorter transcript were observed, in compliance with their zygosity (Fig. 1b
141 and Supplementary Fig. 1f). The Δ ex5 transcript was also detected in healthy control PHA blasts (3%)
142 and fibroblasts (6%), indicating the presence of a naturally occurring low-abundance isoform (Fig. 1b
143 and Supplementary Fig. 1e), consistent with the transcripts documented in the Ensembl genome browser
144 (ENST00000635082.1). We considered the possibility that c.829+5G>T represents a leaky splice
145 variant, however, based on targeted RNA sequencing (Supplementary Fig. 1g), RT-PCR
146 (Supplementary Fig. 1h), and reverse transcription quantitative PCR (RT-qPCR) (Supplementary Fig.
147 1i), we found no evidence supporting this. Although aberrant splicing arising from c.829+2T>G was not
148 investigated, the consequences of c.829+2T>G are expected to coincide with c.829+5G>T as it

149 inactivates the consensus splice donor site in intron 5, demonstrated by the *in silico* splice prediction
150 tools (Supplementary Table 2).

151 **Reduced ATR protein in absence of full-length ATRIP**

152 Alternative splicing of *ATRIP* pre-mRNAs harboring c.829+5G>T or c.829+2T>G variants results in
153 Δ ex5 and a subsequent shift of the reading frame (r.671_829del). At the amino acid level, this translates
154 into a serine to arginine substitution at position 224, immediately followed by the premature stop codon
155 TAG (p.(Ser224ArgfsTer2)) (Fig. 1d). Using western blot, we confirmed absence of full-length ATRIP
156 in both fibroblasts and Epstein-Barr virus immortalized lymphoblastoid cell lines (EBV-LCLs) of F1Pt
157 (Fig. 1e and Supplementary Fig. 1j, k). In absence of full-length ATRIP, ATR expression was strongly
158 reduced in both cell types, while parental LCLs from F1Fa showed an approximately 50% reduction in
159 both ATR and ATRIP protein levels. In line with the presumed co-dependency of ATRIP and ATR,
160 fibroblasts from an ATR patient (F02-98)¹² exhibited strongly reduced ATRIP levels (Fig. 1e and
161 Supplementary Fig. 1k). In contrast, expression levels of interaction partners RPA1 and TOPBP1 were
162 undisturbed by the absence of ATRIP (Fig. 1e and Supplementary Fig. 1j, k).

163 **Mutant ATRIP is loss-of-function**

164 The premature translation stop as a consequence of Δ ex5 is anticipated to trigger nonsense-mediated
165 mRNA decay (NMD). When abolishing NMD using puromycin, equal quantities of both Δ ex5 (\pm 380bp,
166 51%) and full-length (\pm 538bp, 49%) amplicons were observed in cDNA from EBV-LCLs of F1Fa (Fig.
167 1f). However, in absence of puromycin, half of the Δ ex5 transcript persisted (\pm 380bp, 36% vs \pm 538bp,
168 64%), indicating that the Δ ex5 transcript resulting from c.829+5G>T might translate into a truncated
169 protein. Due to the unavailability of high-quality antibodies targeting the N-terminal region of ATRIP,
170 we confirmed the presence of a truncated protein by overexpressing 3xFLAG-tagged wild type (wt) or
171 mutant (mut) ATRIP, which resulted in a stable 82kDa and 37kDa protein, respectively (Fig. 1h).
172 According to the remaining amino acid sequence (AA1-224), this 37kDa ATRIP protein contains both
173 the coiled-coil and RPA binding motif but lacks the TOPBP1 and ATR binding domains (Fig. 1g)⁴⁰. To
174 assess this, HEK293T cells were co-transfected with ATR-V5, RPA1-Myc, and the 3xFLAG-wtATRIP
175 or 3xFLAG-mutATRIP constructs. Upon pulldown with an anti-FLAG antibody, immunoblotting
176 confirmed that the 37kDa mutant was able to interact with RPA1, in accordance with earlier mutational
177 studies⁴¹⁻⁴³. No ATR protein could be visualized, indicating an abolished interaction. Faint TOPBP1
178 was detected, but at levels comparable to those of the IgG controls, suggestive of a defective interaction
179 with TOPBP1 (Fig. 1h).

180 ***ATRIP* c.829+5G>T is associated with CD4⁺ T, B, and NK lymphopenia and progressive 181 neutropenia**

182 Given the features of immunodeficiency in patients with ATRIP deficiency, we set out to characterize
183 the immunophenotype of F1Pt. In line with the RTIs and a severe varicella-zoster infection, F1Pt
184 presented with reduced numbers of B and NK cells (Fig. 2a and Table 1). Low numbers of CD4⁺ T cells
185 and an inverted CD4⁺/CD8⁺ ratio were noted (Fig. 2a and Table 1). These features were unique to F1Pt,
186 as both the heterozygous parents and the wild-type sister had immune profiles similar to healthy controls
187 (HCs) (Fig. 2b). Immunoglobulin substitution therapy related to IgG2 subclass deficiency and a specific
188 pneumococcal antibody deficiency, along with azithromycin maintenance, effectively controlled the
189 RTIs (Fig. 2c and Table 1). Over time, F1Pt developed a progressive neutropenia in presence of
190 antineutrophil cytoplasmic antibodies, which was responsive to emergency granulopoiesis during acute
191 infections (Fig. 2d). Between the ages of 16-20, F1Pt presented with recurrent autoimmune hemolytic

192 anemia (AIHA) that subsided upon treatment with corticosteroids and anti-CD20 monoclonal antibody
193 (mAb) treatment (Fig. 2e).

194 **Expansion of T effector cells, low levels of CD16⁺ NK and absent MAIT, and iNKT lineages**

195 To study the impact of ATRIP deficiency on the lymphocyte compartment in more detail, we performed
196 high-parametric flow cytometry (FCM) (Fig. 2f, g) on PBMCs of F1Pt and age-matched HCs. Among
197 the CD4⁺ and CD8⁺ T cells in F1Pt, we noted expansion of effector cells at the expense of naïve T cells
198 (Fig. 2f). Especially in the CD8⁺ T cell compartment, increased percentages of HLA-DR⁺ and CD27⁻
199 CD28⁻ T cells were noted, indicating ongoing activation and exhaustion. Similarly, CD95⁺ double-
200 negative (DN) T cells were expanded. In addition to diminished naïve T cell levels, we noted the absence
201 of both mucosal-associated invariant T (MAIT) and invariant natural killer T (iNKT) cells. The observed
202 NK lymphopenia was characterized by a selective reduction of CD16⁺ NK cells (Fig. 2f). NK cytotoxic
203 potential was assessed and revealed normal CD107a upregulation upon stimulation with K652. In line
204 with the higher proportion of CD56^{bright} NK cells in F1Pt, perforin expression was reduced (data not
205 shown). In a similar approach, the B cell and innate compartment was investigated in detail (Fig. 2g).
206 CD21^{lo} B cells were expanded in F1Pt at the expense of CD21^{hi} memory B cells and plasmablasts. In
207 the innate compartment, we noted lower percentages of type 1 dendritic cells (DC1) and plasmacytoid
208 (p)DCs. Among monocyte subsets, both inflammatory and CD169⁺ expressing monocyte subsets were
209 increased. Manual gating of the FCM data confirmed the main findings of this analysis (Supplementary
210 Fig. 2a-c).

211 **TCR oligoclonality and altered antibody class switch recombination in absence of ATRIP**

212 Given the diminished levels of naïve T cells and absence of MAIT cells in F1Pt, we looked for potential
213 disparities in the recombinational processes of antigen receptors. To study this in more detail, CITE-seq
214 (cellular indexing of transcriptomes and epitopes by sequencing) combined with T cell receptor (TCR)
215 and B cell receptor (BCR) sequencing of PBMCs, collected prior to anti-CD20 mAb treatment, was
216 performed. CITE-seq profiling confirmed the observed immune defects (Fig. 3a, and Supplementary
217 Fig. 3a). By visualizing both the usage and pairing of unique *TRAV* and *TRBV* genes, we observed a
218 decreased diversity in the TCR repertoire in F1Pt compared to HCs (Fig. 3b, c and Supplementary Fig.
219 3b, c). Oligoclonality was most evident in CD8⁺ effector memory (T_{EM}) cells, suggesting clonal
220 expansion (Fig. 3b, c). Using a similar analysis based on *IGH* transcripts, we observed no restrictions in
221 BCR repertoire diversity (Supplementary Fig. 3e, f). Changes in complementarity-determining region 3
222 (CDR3) length and composition have been described in immunodeficiencies^{44,45}. Comparing the CDR3
223 length profiles of *TRAV*, *TRBV*, and *IGH* transcripts, we observed no consistent differences between
224 F1Pt and HCs (Fig. 3d and Supplementary Fig. 3d, g). These findings are indicative of competent V(D)J
225 recombination, suggesting adequate repair by non-homologous end-joining (NHEJ) in the absence of
226 ATRIP.

227 Affinity maturation and isotype switching of antibodies require efficient DNA recombination processes
228 called somatic hypermutation and class switch recombination (CSR), respectively. A potential role for
229 ATR signaling in CSR has been suggested in previous studies, owing to its regulatory function in DNA
230 replication and proliferation^{15,46,47}. Using a modified version of linear amplification-mediated high-
231 throughput genome-wide translocation sequencing (LAM-HTGTS), we assessed CSR patterns in
232 ATRIP deficient PBMCs^{48,49}. Our results revealed an altered isotype switching profile in F1Pt, with
233 decreased proportions of recombination between S_μ and S_{γ1}, S_{γ2}, and S_{γ4} (Fig. 3e). A marked increase
234 in inversional S_μ-S_{γ1} and S_μ-S_{γ4} junctions was noted, indicating reduced efficiency in IgG subclass
235 switching (Fig. 3f). We observed increased usage of longer microhomologies (≥10 bp) at the S_μ-S_α
236 switch junctions in F1Pt as compared to HCs (Fig. 3g), indicating increased repair via alternative end

237 joining. Given that alternative end joining depends on DNA end resection during early S phase, these
238 results are suggestive of disruptions in cell cycle dynamics⁵⁰.

239 ***ATRIP* c.829+5G>T presents with a DNA repair signature and interferon-driven immune** 240 **dysregulation**

241 We performed Gene Set Enrichment Analysis (GSEA) to examine the differentially expressed genes in
242 PBMCs of F1Pt compared to HCs. Among the most altered biological processes (adj P<0.05; Log2: ±1),
243 we noted a distinct DNA repair signature in PBMCs from F1Pt (Fig. 4a, b and Supplementary Fig. 4a,
244 b), which was also evident in both T effector and NK subsets (Supplementary Fig. 4c, d). Likely related
245 to F1Pt's autoimmune phenotype, an upregulated interferon (both type I and II) response was observed.
246 Analysis of cytokine expression in serum samples collected during an episode of AIHA and after
247 successful treatment with anti-CD20 mAb confirmed increased interferon signaling (IFN γ and IP10)
248 and indicated both innate and T lymphocyte subset activation (IL-10, IL-18, IL-27, IL-31) (Fig. 4c).
249 While treatment of AIHA with corticosteroids and anti-CD20 mAb resulted in partial reduction of all
250 cytokines, the Th2-signature cytokines IL-10 and IL-31 persisted. FCM analysis confirmed the response
251 to anti-CD20 mAb therapy, with partial normalization of interferon-regulated proteins CD64 and CD169
252 on classical monocytes (Fig. 4d). While effectively targeting B cells, anti-CD20 mAb treatment did not
253 normalize NK and T cell subset percentages, nor did it normalize T cell maturation (Supplementary Fig.
254 4e-g). Additionally, treatment had minimal effect on T cell activation, as indicated by increased levels
255 of ICOS, OX40, and PD1 (Supplementary Fig. 4h).

256 **Impaired T cell proliferation in absence of *ATRIP***

257 Considering that GSEA and CSR analyses indicated dysregulated DNA repair and cell cycle dynamics
258 in F1Pt cells, we proceeded to investigate the proliferative capacity of T cells in more detail. The
259 lymphocyte transformation test (LTT) performed on whole blood of F1Pt revealed reduced or absent T
260 cell proliferation upon stimulation with both mitogens and specific antigens (candida, tetanus),
261 respectively (Fig. 4e). Using a more comprehensive study determining both the precursor frequency
262 (PF) and proliferation index (PI) of CellTrace Violet (CTV) labeled T cells, we noted a substantial
263 reduction in the proliferation capacity of both CD4⁺ and CD8⁺ T cells of F1Pt upon stimulation with the
264 mitogen PHA (Fig. 4f). In conclusion, the immunophenotype of *ATRIP* deficiency is characterized by
265 defects in all three lymphocytic lineages, an interferon-driven immune dysregulation, and a profound T
266 cell proliferative defect.

267 **Loss of *ATRIP* does not impair ATR recruitment and auto-phosphorylation**

268 Next, we set out to characterize the molecular processes driving disease in absence of *ATRIP*. As
269 localization of ATR to DNA damage sites is a prerequisite for ATR activation, we assessed nuclear ATR
270 foci by immunofluorescence. Unexpectedly, this revealed that F1Pt fibroblasts were competent in
271 forming ATR foci in response to the known ATR-activating DNA damage inducers mitomycin C
272 (MMC), a DNA interstrand crosslinker (ICL), UV, and ionizing radiation (IR). In addition, F02-98
273 fibroblasts (*ATR* patient) showed normal recruitment of ATR (Fig. 5a and Supplementary Fig. 5a),
274 despite substantially reduced total ATR protein levels (11% of HC levels; Supplementary Fig. 1g). No
275 significant differences in foci number per cell were observed between HC and F1Pt fibroblasts following
276 MMC and IR treatment, whereas UV exposure resulted in a slightly higher amount of ATR foci in F1Pt
277 and F02-98 fibroblasts. The higher number of spontaneous foci in mock conditions suggests persistent
278 DNA damage (Fig. 5a and Supplementary Fig. 5a).

279 Next, ATR-dependent substrate phosphorylation was investigated as a measure for ATR activation.
280 Autophosphorylation of ATR on residue T1989 has been identified as a hallmark of its active state and

281 is regulated by DNA damage induction^{51,52}. T1989 phosphorylation (hereafter referred to as pATR) was
282 readily detected in untreated F1Pt and F02-98 cells and further increased upon UV treatment, although
283 absolute pATR levels were reduced compared to control fibroblasts (Fig. 5b and Supplementary Fig.
284 5b). Interestingly, when expressing UV-induced pATR levels as a fold increase over basal levels, a
285 similar 1.5-fold induction was observed for F1Pt, F02-98, and control cells (Fig. 5c). Of note, the
286 specificity for T1989 phosphorylation was confirmed using lambda phosphatase (λ PPase) treatment
287 (Supplementary Fig. 5c). Full activation of CHK1, the major downstream effector of the ATR signaling
288 pathway, requires phosphorylation by ATR⁶. Following UV exposure, CHK1 phosphorylation on
289 residue S317 (indicated as pCHK1) was reduced in both F1Pt and F02-98 fibroblasts compared to HCs
290 (Fig. 5b and Supplementary Fig. 5b). This reduction was also evident when the fold induction over basal
291 levels was quantified (Fig. 5c). Of note, total CHK1 levels were reduced in F02-98, but not in F1Pt
292 fibroblasts (Fig. 5b), a possible consequence of the high passage number and senescence of the F02-98
293 cells⁵³.

294 DNA repair intermediates formed after UV irradiation trigger H2AX phosphorylation at S139 (known
295 as γ H2AX), a process mainly mediated by ATR and found to be impaired in ATR patient cells^{12,15,54,55}.
296 Following UV exposure, a strong pan-nuclear γ H2AX positivity was readily noted via
297 immunofluorescence in control fibroblasts (Fig. 5d). In contrast, γ H2AX was almost entirely absent in
298 EdU- nuclei of F1Pt fibroblasts, while it was retained in EdU+ nuclei. Consistent with this, FCM
299 analysis of γ H2AX expression in EdU- cells showed decreased MFI values in F1Pt (Fig. 5e). In
300 conclusion, while the exact mechanism of ATR recruitment and activation remains unclear, our
301 observations indicate that ATRIP is dispensable for the initial recruitment and subsequent
302 autophosphorylation of ATR. Downstream ATR substrate phosphorylation was impaired but not
303 abolished, providing evidence for an inadequate ATR signaling response in absence of ATRIP.

304 **Compromised replication stress response and cell cycle progression in absence of ATRIP**

305 Replication stress induces stalling of replication forks and exposes single-stranded DNA (ssDNA) that
306 is rapidly coated with RPA. Subsequent ATR activation safeguards genomic stability and prevents
307 further fork stalling and collapse by restraining fork progression and suppressing origin firing. In
308 addition, the ATR kinase is responsible for stabilizing stalled forks, thereby facilitating fork restart upon
309 resolved stress. We aimed to thoroughly define the *in vitro* phenotype associated with ATRIP deficiency
310 by investigating the cellular consequences of genotoxic treatments.

311 Previous studies noted comparable cell cycle distributions in untreated cells of ATR patients and
312 HCs^{14,15}. Consistent with this, we observed no differences in cell cycle ratios between F1Pt and control
313 fibroblasts or PHA blasts (Fig. 6a, b and Supplementary Fig. 6a). To investigate the replication stress
314 response, we treated F1Pt fibroblasts with MMC and assessed the replicative response using FCM (Fig.
315 6a). Whereas HC cells efficiently suppressed origin firing and fork progression upon MMC treatment
316 (indicated by reduced EdU intensity), F1Pt cells showed no substantial response (Fig. 6c). To verify
317 ATR involvement, we pretreated cells with an ATR inhibitor (ATRi). Upon ATRi treatment, the EdU
318 intensity of HC cells mimicked that of ATRIP deficient cells, confirming impaired ATR signaling in
319 F1Pt cells. Additionally, DAPI histograms of S phase cells showed accumulation of HC cells in late S
320 phase following MMC, in contrast to F1Pt cells that retained a diffuse DAPI profile similar to non-
321 treated cells.

322 In absence of timely ATR activation, excessive origin firing results in accumulation of RPA-ssDNA
323 nucleoprotein filaments, progressively depleting the nuclear pool of RPA and preceding compromised
324 fork integrity⁵⁶. Using immunofluorescence, we observed significantly higher RPA2 intensity in S phase
325 F1Pt fibroblasts compared to HCs, both in mock and upon hydroxyurea (HU) treatment (Fig. 6d and

326 Supplementary Fig. 6b). HU induces widespread fork stalling through dNTP depletion, as evidenced by
327 the complete loss of EdU incorporation after 3h of HU treatment (Supplementary Fig. 6c)⁵⁷. Additional
328 treatment with ATRi further increased RPA2 intensity in both F1Pt and HCs, although the RPA2
329 intensity levels in HCs did not reach those observed in F1Pt.

330 Next, we determined whether patient fibroblasts retained their ability to recover from acute HU-induced
331 replication stress. While HC cells readily resumed DNA synthesis, F1Pt fibroblasts demonstrated
332 reduced levels of fork recovery following replication fork stalling, indicated by decreased EdU
333 incorporation following HU release. Combined HU and ATRi treatment impeded replication recovery
334 in HC cells and further intensified the observed impairment in F1Pt cells (Fig. 6e).

335 Regulation of cell cycle progression is crucial to allow repair of damaged DNA and completion of DNA
336 replication prior to mitosis. Pronounced G2/M arrest has been described as a hallmark of ATR
337 deficiency, reflecting the direct consequence of acquired DNA damage during the S phase⁵⁶
338 Accordingly, F1Pt fibroblasts and PHA blasts accumulated in the G2/M phase after MMC exposure
339 (Fig. 6f and Supplementary Fig. 6a). ATRi treatment in HC cells resulted in similar checkpoint
340 activation, confirming that the observed G2/M arrest is a direct result of defective ATR signaling in the
341 S phase (Fig. 6f). An additional established function of ATR is the G2/M checkpoint activation in
342 response to IR, preventing premature mitotic entry in the presence of severely damaged DNA
343 (Supplementary Fig. 6d)^{58,59}. In ATRIP deficient cells, the ATR signaling pathway retained sufficient
344 activity to initiate G2/M checkpoint arrest upon irradiation, albeit at a significantly lower level compared
345 to HC cells. (Supplementary Fig. 6d).

346 As our data did not indicate significant deviations in the cell cycle distribution of unperturbed patient
347 cells, we extended our investigations to assess the S phase kinetics using an EdU pulse-chase assay (Fig.
348 6g and Supplementary Fig. 6e)⁶⁰. We found that unperturbed F1Pt PHA blasts displayed a prolonged S
349 phase, compared to HC cells. Exposure to MMC and UV increased the S phase-delay in both F1Pt and
350 HC cells, with a more pronounced effect in F1Pt cells. In light of these findings, we speculated that
351 proficient ATR signaling is essential for facilitating T cell proliferation under conditions of excessive
352 replicative stress. Indeed, upon treatment with MMC, we observed a strongly diminished proliferative
353 response and subsequent division rate of CTV-labeled T cells of F1Pt (PF and PI, respectively),
354 particularly in CD4⁺ T cells (Fig. 6h and Supplementary Fig. 6f).

355 Taken together, defective ATR signaling in ATRIP deficient cells results in an impaired replication
356 stress response, consequently compromising cell cycle progression and proliferation.

357 ***ATRIP* c.829+5G>T cells display DNA damage, chromosomal sensitivity, and impeded survival**

358 The consequences of compromised replication and subsequent accumulation of DNA damage typically
359 manifest post-mitosis, resulting in chromosomal breakage and cell death. To assess spontaneously
360 occurring DNA damage, we examined the formation of γ H2AX nuclear foci, a well-established marker
361 of DNA double-strand breaks (DSBs). Quantification of γ H2AX in EdU- cells revealed a significantly
362 higher number of foci in F1Pt and F02-98 fibroblasts (Fig. 7a and Supplementary Fig. 7a). To evaluate
363 DSB repair fidelity, we analyzed micronucleus (MN) formation using 3 different assays: the G0 MN
364 assay, the MMC MN test, and a newly developed S MN assay (Fig. 7b). F1Pt PHA blasts showed
365 increased spontaneous MN levels with the S MN assay, opposed to the normal levels observed with the
366 G0 MN test (Fig. 7c). This discrepancy suggests that DNA damage and subsequent chromosomal
367 breakage only becomes apparent after multiple cell cycles have been completed. Correspondingly,
368 immunofluorescence preparations of proliferating fibroblasts showed higher MN frequencies in F1Pt
369 and F02-98 compared to HCs (data not shown).

370 Next, we assessed chromosomal sensitivity to IR and MMC. No increase in radiation-induced MN yields
371 was observed in F1Pt PHA blasts with the G0 MN assay, indicating a proficient NHEJ DSB repair
372 pathway. Irradiation during the S phase led to a higher yield of MN (Fig. 7d and Supplementary Fig.
373 7b), highlighting a specific S phase sensitivity to radiation in absence of ATRIP, a phenotype not earlier
374 associated with cells deficient in ATR signaling^{12,61}. As anticipated, F1Pt cells also showed impaired
375 ICL repair, reflected by the increase in MN formation in the presence of MMC (Fig. 7d). No increase in
376 MN levels was detected in PHA blasts of the parents using both the MMC and S MN assay (Fig. 7c, d
377 and Supplementary Fig. 7b), indicating that the heterozygous presence of the c.829+5G>T variant does
378 not compromise ATR signaling.

379 Notably, persistent DNA damage accumulated during unperturbed replication in F1Pt and F02-98
380 fibroblasts negatively affected cell survival (Fig. 7e, g). In addition, we meticulously quantified cell
381 death and cell proliferation in absence of functional ATR signaling following DNA damage induction
382 by MMC, UV, or IR (Fig. 7f-i and Supplementary Fig. 7e, f). Treatment with 0.2 µg/ml MMC and 20
383 J/m² UV revealed a profound sensitivity of F1Pt and F02-98 fibroblasts, whereas cell survival of control
384 fibroblasts was slightly impaired by MMC and unaffected by UV (Fig. 7g). These results confirm the
385 previously described MMC and UV hypersensitivity in absence of functional ATR signaling^{12,15,61}. In
386 line with the G0 and S MN assay results of PHA blasts, exposure to 10 Gy IR only elicited a slight
387 increase in cell death in F1Pt and F02-98 fibroblasts (Fig. 7g). Combined treatment of ATRi and a DNA
388 damage inducer progressively compromised cell survival. Although minor in the case of F1Pt and F02-
389 98 fibroblasts, this increase was consistently observed for all three genotoxic treatment conditions,
390 suggesting residual ATR kinase activity (Fig. 7h).

391 In contrast to F1Pt and F02-98 fibroblasts, the combined treatment of ATRi with genotoxic stressors
392 profoundly impaired cell survival in HC fibroblasts (Fig. 7h). To assess redundancy with the other DDR
393 kinases, we quantified cell death rates in the presence of specific inhibitors targeting ATM and DNA-
394 PKcs. ATM inhibition (ATMi) resulted in particularly high lethality in combination with ATRIP
395 deficiency (F1Pt) or hypomorphic *ATR* variants (F02-98), contrasting with the response observed in HC
396 fibroblasts (Fig. 7h and Supplementary Fig 7d). This was most evident upon IR-induced genotoxic
397 stress, implying a substantial redundancy between the ATR and ATM kinase. Concomitant DNA-PK
398 inhibition with genotoxic treatment did not evoke additional sensitivities in F1Pt, F02-98, or HC
399 fibroblasts (Supplementary Fig. 7c, d). In conclusion, these findings demonstrate that loss of ATRIP
400 results in chromosomal sensitivity and compromised cell viability, although some residual ATR
401 signaling was retained. Moreover, concurrent ATM kinase activity is needed to mitigate the most
402 detrimental effects of genotoxic stressors, as previously suggested for ATR deficient cells^{15,61}.

403 **Modeling of ATRIP variants by CRISPR-Select^{TIME} exposes reduced cell fitness**

404 Finally, to confirm the impact of the c.829+5G>T and c.829+2T>G *ATRIP* variants in an independent
405 cellular model, cell fitness was assessed using the CRISPR-Select^{TIME} methodology³⁸. To accurately
406 study the effects of these variants, an MCF10A cell line harboring only one functional *ATRIP* or *ATR*
407 allele was generated (Fig. 8a and Supplementary Fig. 8a). In addition to the variants identified in this
408 study, a hypomorphic leaky splice variant in *ATR* (c.2022A>G, homozygous in F02-98¹²), the proposed
409 causal *ATRIP* variants identified in patient CV1720¹⁴ (c.2278C>T and c.248-14A<G), and a
410 homozygous benign *ATRIP* splice variant present in gnomAD v4.0.0 (c.2056-6_2056-3del) were
411 modeled. As expected, the presence of the c.2022A>G *ATR* variant resulted in strongly reduced cell
412 fitness (Fig. 8b). CRISPR-Select^{TIME} revealed similarly large effect sizes for both *ATRIP* splice variants,
413 c.829+5G>T (homozygous in F1Pt) and c.829+2T>G (homozygous in F46.1). Moreover, we confirmed
414 the anticipated neutrality of the homozygous *ATRIP* variant reported in gnomAD v4.0.0 (c.2056-

415 6_2056-3del). Surprisingly, for the reported *ATRIP* variants of patient CV1720, reduced fitness was
416 only evident for the c.2278C>T variant. Although abnormal splicing was observed in presence of the
417 second *ATRIP* allele of patient CV1720, we were unable to validate the causality of the candidate variant
418 c.248-14A>G using CRISPR-Select^{TIME} (Fig. 8c and Supplementary Fig. 8b), which might reflect the
419 originally reported hypomorphic nature of this variant¹⁴. Given the role of both ATR and ATRIP in
420 regulating DNA replication and proliferation dynamics, application of the CRISPR-
421 Select^{TIME} methodology in a mono-allelic ATRIP cell line appeared particularly suitable to establish the
422 pathogenic role of the identified *ATRIP* variants c.829+5G>T and c.829+2T>G, next to the known
423 c.2278C>T variant. Moreover, frequencies of these variants and their corresponding internal controls
424 (frameshifts) were strikingly comparable, indicating similar selection against both editing outcomes
425 (Fig. 8c and Supplementary Fig. 8b).

426 DISCUSSION

427 In this study, we demonstrated that biallelic loss-of-function (LOF) *ATRIP* variants result in human
428 disease, characterized by short stature, microcephaly, intellectual disability, and immunodeficiency. The
429 causal role of the pathogenic *ATRIP* variants is supported by multiple lines of evidence; (1) the presence
430 of homozygous novel or rare variants with a similar LOF consequence on protein level in two patients
431 of independent ancestry, (2) the complete absence of homozygous LOF *ATRIP* variants in the non-
432 affected population (cfr. gnomAD), (3) the finding of an impaired replication stress response associated
433 with disturbed proliferation and survival in primary patient cells, and (4) reduced cell fitness when
434 introducing these variants in an independent cellular model.

435 Ablation of *ATR*, *TOPBP1*, or *CHK1* in murine models has consistently resulted in embryonic lethality,
436 emphasizing the essential nature of the *ATR* signaling pathway^{7,8,59,62,63}. This is further illustrated by the
437 identification of exclusively hypomorphic *ATR* mutations in patients with microcephalic primordial
438 dwarfism (MPD)^{12,14-16}. In a similar vein, it has been suggested that *ATRIP* deficiency would be
439 incompatible with life. However, our study demonstrates that LOF *ATRIP* variants are tolerated to some
440 extent in human individuals, albeit resulting in a severe MPD phenotype. In line with our findings,
441 knock-out *atrip* zebrafish were also shown to be viable but displayed a severely compromised body
442 length and lifespan, suggesting a crucial role of *atrip* in growth and development during the juvenile
443 stage⁶⁴.

444 *ATRIP* plays a crucial role in facilitating stabilization, recruitment, and activation of the *ATR*
445 kinase^{11,40,65}. Studies using both cellular models and patient cells have shown that partial or complete
446 *ATRIP* loss results in a significant reduction in *ATR* protein levels^{11,14,41}. This co-dependency between
447 *ATR* and *ATRIP* for protein stability is further evidenced by our data, showing markedly diminished
448 *ATR* levels in complete absence of *ATRIP*. Several lines of evidence have demonstrated that *ATRIP*
449 acts as a sensor of RPA-ssDNA nucleoprotein filaments, promoting *ATR* recruitment and subsequent
450 activation of downstream substrates^{17,65}. Interestingly, an early mutational study detected efficient
451 *CHK1* phosphorylation in the presence of mutated *ATRIP* devoid of its RPA-binding domain⁴¹.
452 Correspondingly, our findings revealed that the remaining pool of *ATR* was able to form foci and
453 autophosphorylate (T1989 phosphorylation) upon exposure to genotoxic stressors in absence of *ATRIP*,
454 although at lower levels. These results suggest that *ATRIP* is required for *ATR* stability but not for *ATR*
455 recruitment and activation. While both *TOPBP1* and *ETAA1* are able to activate *ATR*, only the *ATR*-
456 *TOPBP1* axis requires *ATRIP* for recruitment to RPA-ssDNA filaments^{17,22,40}. It remains to be clarified
457 whether binding and activation of *ATR* by *ETAA1* is retained upon *ATRIP* loss. We speculate that
458 interactions with *ETAA1* and potentially other unanticipated complex partners may underly the ability
459 of *ATR* to recognize DNA damage and display kinase activity in an *ATRIP*-independent manner.

460 Studies using murine models have provided compelling evidence implicating *ATR* signaling in the
461 development, maturation, and maintenance of the immune system⁶⁶⁻⁷⁰, an association which had not
462 been clearly described in humans to date. These mice consistently presented with developmental
463 abnormalities analogous to MPD and features of premature ageing, demonstrating that unresolved
464 replicative stress, proliferative failure, and cellular senescence likely underly both the developmental
465 and immunological phenotype. The association of MPD with immunodeficiency is further supported by
466 an emerging class of inborn errors of immunity (IEI) linked to monogenic defects in DNA replication
467 factors^{29,31-34,71}. These disorders typically present a combination of immunodeficiency with perturbed
468 growth, microcephaly, progeroid features, and developmental abnormalities. All three *ATRIP* patients
469 had clinical features suggestive for immunodeficiency, and the immunophenotype - characterized by
470 lymphopenia and neutropenia - draws intriguing parallels to observations in other DNA replication-
471 associated disorders. Our data revealed that *ATRIP* loss compromises the replication stress response,

472 leading to a DNA repair signature in immune cells *in vivo* and impaired lymphocyte proliferation *in*
473 *vitro*. Despite our observations in ATRIP deficient patients, no definite immunological phenotype has
474 been observed in patients with biallelic *ATR* mutations (based on personal correspondence with
475 respective clinicians). Although Mokrani-Benhelli et al.¹⁵ noted minor immune irregularities in a 9-year
476 old patient with biallelic *ATR* mutations, drawing parallels to our patient FIPt, the phenotype was
477 relatively mild and no up-to-date immunological data could be obtained. Several explanations for these
478 disparate observations are possible; (1) the hypomorphic nature of the *ATR* mutations may mitigate the
479 impact of ATR deficiency on the human immune system, (2) ATR signaling in immune cells such as
480 lymphocytes is critically dependent on ATRIP, (3) ATRIP has ATR-independent functions in the human
481 immune system. In line with this, considerable heterogeneity in immunological features is also observed
482 in both DNA repair and DNA replication-associated IEI, highlighting that mutations within the same
483 cellular processes can lead to diverse phenotypes^{31,32,71,72}. Finally, several older studies reported
484 immunological abnormalities, such as pancytopenia, in patients with a phenotypical diagnosis of Seckel
485 syndrome⁷³⁻⁷⁶. It is worth noting, however, that the molecular causes of Seckel syndrome had not yet
486 been identified at that time, potentially leading to misdiagnoses due to overlapping features with other
487 MPD-like disorders^{77,78}. More studies, comprehensively describing the immunological phenotype in
488 molecularly characterized disorders of DNA replication and DNA repair, will be required to further our
489 understanding of the role of ATR and ATRIP in the biology of immune cells.

490 In summary, our study provides evidence supporting *ATRIP* as a disease-associated gene in MPD and
491 IEI and offers valuable insights into the cellular and immunological characteristics. Our findings
492 challenge the conventional paradigm of the ATR-ATRIP interaction, underscoring the need for further
493 investigation into the molecular mechanisms governing ATR activation upon DNA damage. Although
494 our data suggests an essential role for ATRIP in safeguarding immune cells against the consequences of
495 unresolved replicative stress, it remains unclear whether this reflects an unidentified noncanonical
496 function of ATRIP or this is mediated by the ATR signaling pathway. Careful clinical monitoring and
497 additional research are needed to further delineate the phenotypic spectrum associated with both biallelic
498 *ATR* and *ATRIP* mutations and to better understand the cellular mechanisms driving the immunological
499 phenotype.

500 MATERIAL AND METHODS

501 Study approval

502 Ethical approval for this study was granted by the ethics committee of Ghent University Hospital in
503 Belgium (2012/593 and 2019/1565). Clinical data and samples were collected with informed consent
504 from the participants of the study, in accordance with the 1975 Helsinki Declaration.

505 Cell culture

506 Lymphoblastoid cell lines (LCLs) were derived from blood following EBV transformation. LCLs were
507 maintained in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with GlutaMAX,
508 10% FBS (Bodinco and Tico Europe), 1% penicillin-streptomycin (10,000 U/mL; Gibco), 1 mM sodium
509 pyruvate (Gibco) and 50 μ M 2-mercaptoethanol (Gibco). PHA blasts were generated by culturing
510 cryopreserved isolated peripheral blood mononuclear cells (PBMCs) in LCL medium supplemented
511 with 2% phytohemagglutinin-M (PHA-M; Gibco). HEK293T cells (The American Type Culture
512 Collection (ATCC)) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented
513 with 10% FBS, 1% penicillin-streptomycin (10,000 U/ml), 2mM GlutaMAX (Gibco). Primary human
514 dermal fibroblast cells were cultured in DMEM supplemented with 10% FBS, 1% penicillin-
515 streptomycin (10,000 U/ml), 2mM GlutaMAX, 0.1 mM sodium pyruvate, and 50 μ M 2-
516 mercaptoethanol. MCF10A cells (ATCC; CRL-10317) were cultured in Dulbecco's Modified Eagle
517 Medium:Nutrient Mixture F-12 (DMEM / F-12) (Thermo Fisher Scientific; 31330038), supplemented
518 with 5% horse serum (Thermo Fisher Scientific; 16050122), 1% Penicillin/Streptomycin (Thermo
519 Fisher Scientific; 15070063), 10 μ g/ml insulin (Sigma-Aldrich; I1882), 0.5 μ g/ml hydrocortisone
520 (Sigma-Aldrich; H0888-1G), 20 ng/ml EGF (Peprotech; AF-100-15), and 100 ng/ml cholera toxin
521 (Sigma-Aldrich; C8052-5MG). ATR deficient fibroblasts from a previously described ATR patient
522 (F02-98) were purchased from Coriell institute (GM18366)¹². All cell lines were incubated at 37°C with
523 5% CO₂.

524 Sequencing analysis

525 Trio whole exome sequencing (WES) on genomic DNA of the patient and unaffected parents was
526 performed using KAPA HyperExome probes (Roche). Paired-end massive parallel sequencing was
527 performed on a NovaSeq 6000 Instrument (Illumina). Data analysis was performed on an in-house
528 developed platform, in accordance with the American College of Medical Genetics and Genomics and
529 the Association for Molecular Pathology (ACMG-AMP) guidelines⁷⁹. Variant confirmation and
530 segregation analysis was performed by Sanger Sequencing on an ABI 3730 platform (Applied
531 Biosystems).

532 RNA for evaluation of aberrant splicing was obtained using the Maxwell® RSC simplyRNA Tissue Kit
533 on a Maxwell® RSC Instrument (Promega Corporation) from PHA blasts stimulated with 1 μ l/ml PHA-
534 M and 50 μ l/ml interleukin-2 (IL-2) (Sigma-Aldrich), LCLs, and patient-derived dermal fibroblasts.
535 cDNA was synthesized using Superscript III Reverse Transcriptase (Invitrogen) according to
536 manufacturer's recommendations. Amplicon length analysis was performed using a TapeStation
537 (Agilent Technologies) or an ABI 3730 platform (Applied Biosystems).

538 Targeted RNA-sequencing was performed with the SureSelectXT HS2 RNA System kit (Agilent
539 Technologies) using SureSelectXT Human All Exon V7 probes (Agilent Technologies) for target
540 enrichment and sequencing was performed on a NovaSeq 6000 Instrument (Illumina).

541 All primers were purchased from Integrated DNA Technologies and are listed in Supplementary Table
542 5. Nucleotide and protein numbering is in accordance with transcript ENST00000320211 and
543 NM_000057.3, respectively.

544 **RT-qPCR**

545 Fibroblasts from healthy controls and patient F1Pt were lysed in RLT buffer (Qiagen) and stored at -
546 80°C until further processing. RNA was purified using the RNeasy Mini kit (Qiagen) according to
547 manufacturer's protocol. Total RNA was reverse transcribed into cDNA using the SensiFast cDNA
548 Synthesis Kit (Bioline) and real-time quantitative PCR (RT-qPCR) was performed using the
549 LightCycler 480 (Roche). Gene transcript levels were normalized against an endogenous B-actin
550 control. Samples were run in duplicates in two independent experiments. Results are depicted as the
551 relative expression compared to the healthy controls, determined using the $2^{-\Delta\Delta Ct}$ method. To determine
552 mRNA expression levels of a shorter mutant transcript and a transcript containing exon 5 in F1Pt
553 fibroblasts, primers against an amplicon in exon 3-4 and exon 5-6 of ATRIP were used, respectively.
554 Predesigned qPCR primer pairs were ordered from Integrated DNA technologies (<https://eu.idtdna.com>)
555 (primers are listed in Supplementary Table 5).

556 **DNA damage inducers and inhibitors**

557 Cells were irradiated with 254nm ultraviolet radiation (UV-C) in the absence of culture medium using
558 the UVP Crosslinker (Analytikjena) or with X-rays (220kV, 13mA, 0.15mm copper filter, 3Gy/min)
559 using the Small Animal Radiation Research Platform (SARRP) (Xstrahl) at indicated doses. The
560 following genotoxic inducers and chemical inhibitors were used: Mitomycin C (MMC; Sigma-Aldrich),
561 Hydroxyurea (HU; Sigma-Aldrich), ATR kinase inhibitor (ATRi) (20 nM; BAY-1895344, also known
562 as Elimusertib), ATM kinase inhibitor (ATMi) (10 μ M; KU-55933) and DNA-PK inhibitor (DNA-PKi)
563 (2 μ M; KU-57788, also known as NU7441). Inhibitors were added to the medium 1h prior to treatment
564 with genotoxic stressors.

565 **Plasmids and cloning**

566 Plasmid DNA constructs containing the wild type cDNA sequence for ATRIP, ATR, and RPA1 inserted
567 into a modified pcDNA3.1(+) expression vector encoding a N-terminal 3xFlag-tag, a C-terminal V5-
568 tag, or a C-terminal c-Myc-tag, respectively, were purchased from GenScript. Mutant ATRIP plasmid
569 constructs containing the cDNA sequence for wild type ATRIP lacking exon 5 inserted into a
570 pcDNA3.1(+) vector encoding a N-terminal 3xFlag-tag were generated by GenScript. All plasmids were
571 transformed in DH10B or DH5 α Escherichia coli. DNA was isolated using NucleoBond Xtra Midi kit
572 (Macherey-Nagel). HEK293T cells were transiently co-transfected with ATR, RPA1, and either wild
573 type ATRIP or mutant ATRIP plasmid DNA. Transfections were performed with branched 25kDa
574 polyethylenimine (PEI).

575 **Co-immunoprecipitation**

576 Wild type or mutant ATRIP protein was immunoprecipitated by incubating 250 μ g of whole cell lysate
577 with 4 μ g of anti-FLAG antibody (Sigma-Aldrich; F3165) or 4 μ g of isotype-matched IgG antibody
578 (Sigma-Aldrich; 12-371) overnight at 4°C, followed by incubation with Dynabeads Protein G
579 (Invitrogen) for 1h at 4°C. Beads with protein complexes were washed six times with IP High buffer
580 without extra salt and detergents (Nuclear complex Co-IP Kit; Active Motif; 54001). Precipitates were
581 eluted by boiling in Laemmli Sample buffer and analyzed by immunoblotting.

582 **Immunoblotting**

583 Cells were lysed in RIPA (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1%
584 SDS, 50 mM Tris, pH 8.0) (Roche) complemented with protease inhibitors (cOmplete ULTRA; Roche)
585 and phosphatase inhibitors (PhosSTOP; Roche). Soluble fraction was normalized prior to protein
586 separation by SDS-PAGE using a 4–15% Criterion TGX Stain-Free Protein Gel (Bio-Rad) and followed
587 by semi-dry transfer to a nitrocellulose membrane (Bio-Rad). Membranes were blocked with 5% nonfat
588 dry milk (Cell Signaling Technology (CST)) in phosphate buffered saline with 0.1% Tween 20 (PBS-
589 T) or 5% bovine serum albumin (BSA) (Roche) in PBS-T for 1h at room temperature, incubated with
590 primary antibodies overnight at 4°C or for 2h at RT, followed by incubation with secondary antibodies
591 conjugated to horseradish peroxidase (HRP). Membranes were developed using enhanced
592 chemiluminescence reagents (SuperSignal West Dura or Femto; Thermo Fisher Scientific) on a
593 Chemidoc imaging system (Bio-Rad). All immunoblotting experiments were performed at least twice,
594 and representative data are shown. Protein levels were quantified using the Image Lab software (Bio-
595 Rad). All uncropped images can be retrieved in the Source File. The following primary antibodies were
596 probed: anti-Flag (1:1000; Sigma-Aldrich; F3165), anti-V5 (1:1000; Invitrogen; R960-25), anti-c-Myc
597 (1:2000; Abcam; ab9106), anti-ATRIP (1:1000; Cell Signaling Technology (CST); #97687), anti-
598 TOPBP1 (1:2000; Bethyl Laboratories; A300-111A), anti-RPA70/RPA1 (1:2000; Abcam; ab176467),
599 anti-ATR (1:1000; CST; #2790), anti-CHK1 (1:1000; Santa Cruz; sc-8408), anti-phospho-ATR (T1989)
600 (1:1000; Invitrogen; PA5-77873), anti-phospho-CHK1 (S317) (1:1000; CST; #8191), anti- β -tubulin-
601 HRP (1:5000; Abcam; ab21058) and anti-GAPDH-HRP (1:2000; CST; #8884). The secondary
602 antibodies goat anti-mouse IgG (H+L)-HRP (1:10000; Invitrogen; G-21040) and goat anti-rabbit IgG-
603 HRP (1:2000; CST; #7074) were used. To confirm the specificity of the anti-phospho-ATR antibody,
604 the membrane was dephosphorylated using Lambda Protein Phosphatase (New England Biolabs;
605 P0753S). Briefly, the membrane was incubated with blocking buffer containing 400 U/ml Lambda
606 Protein Phosphatase and 1 mM MnCl₂ overnight at 4°C prior to incubation with the primary antibody.

607 **Immunofluorescence**

608 Primary fibroblasts were grown on 22 mm glass coverslips (Menzel Gläser) 24h before starting the
609 experiment. Cells were pulse-labeled with 10 μ M EdU (Click-iT™ Plus EdU Alexa Fluor™ 647
610 Imaging Kit; Invitrogen; C10640) for 30 min and concomitantly treated with a DNA damage inducer.
611 For RPA staining, cells were treated with pre-extraction buffer (0.5% Triton X-100, 20 mM HEPES, pH
612 7.4, 100 mM NaCl, 3 mM MgCl₂, and 300 mM sucrose in distilled water) prior to fixation. At the
613 indicated time post-treatment, cells were fixed with 3% paraformaldehyde (PFA) in PBS for 20 min,
614 followed by simultaneous permeabilization and blocking in 1% BSA (Sigma-Aldrich) and 0.2% Triton
615 X-100 in PBS for 30 min. Primary antibody incubations were performed for 1h at RT with anti- γ H2AX
616 S139 (1:500; BioLegend; 613402) and anti-RPA32/RPA2 (1:500; Merck; MABE285) or overnight at
617 4°C with anti-ATR (1:250; CST; #13934). After washing, coverslips were incubated with secondary
618 antibodies for 1h at RT (goat anti-rabbit Alexa Fluor 488 (1:1000; Invitrogen; A-11008) or goat anti-
619 mouse Alexa Fluor 488 (1:1000; Invitrogen; A-11001)). EdU staining was performed by incubation with
620 Click-iT reaction cocktail according to the manufacturer's protocol. Coverslips were mounted in
621 Fluoromount (Sigma-Aldrich) containing DAPI nuclear stain. Images were acquired with a Leica DM6
622 B microscope (Leica Microsystems) using a HCX PL APO 40x/1.3 oil objective, equipped with Las X
623 software (Leica Microsystems). Identical microscope settings and image processing steps were used for
624 all samples of the same experiment. Quantifications of DNA damage foci and analysis of signal
625 intensities was performed using Fiji software (version 2.9.0). Pooled data from three independent
626 experiments are shown. A minimum of 150 cells were analyzed per experimental condition.

627 **Micronucleus assays**

628 *The G0 and MMC micronucleus assay.* The G0 and MMC micronucleus (MN) assay were performed,
629 as described previously by Beyls et al.⁸⁰ and Francies et al.⁸¹, respectively. Briefly, fresh whole blood
630 cultures were prepared by adding 0.5 ml blood to 4.5 ml RPMI. The culture medium was supplemented
631 with 10% FBS and 1% penicillin-streptomycin. The cultures were irradiated with 0.5 or 1 Gy (G0 MN
632 assay) or treated with 0.02 µg/ml MMC (MMC MN assay) and subsequently stimulated with 2% PHA-
633 M. Cytochalasin B (6 µg/ml; Sigma-Aldrich) was added to block cytokinesis 23h post-stimulation. After
634 70h culture time, cells were harvested and exposed to a cold hypotonic shock with 0.075 M KCl and
635 fixed in ice-cold methanol/acetic acid solution. Acridine orange (10 µg/ml; Sigma-Aldrich) stained
636 slides were scored according to the criteria described by Fenech et al.⁸² MN were scored manually on a
637 fluorescence microscope in 1000 binucleate (BN) cells per condition.

638 *The S micronucleus assay.* Fresh whole blood cultures were set-up as described above and cell
639 proliferation was immediately stimulated with 2% PHA-M. Following 96h of culture, the cells were
640 pulse labeled with 10 µM EdU for 30 min, irradiated with 0.5 or 1 Gy, and cytochalasin B (6 µg/ml;
641 Sigma-Aldrich) was added. After an additional 24h of culture, the cells were harvested and fixed
642 according to the G0 MN protocol described previously. Slides were prepared and the cells were
643 additionally fixed in 3% PFA for 20 min and permeabilized with ice-cold 0.2% Triton X-100 for 10
644 min. Subsequently, EdU staining was performed according to the manufacturer's protocol and the slides
645 were mounted in Fluoromount containing DAPI nuclear stain. MN were scored in 1000 EdU positive
646 BN cells per condition.

647 **Flow cytometry**

648 *Cell cycle analysis.* Fibroblasts were seeded at a density of 7,000 cells/cm² and cultured for 24h. The
649 cells were exposed to a DNA damage inducer (0.02 µg/ml MMC, 200 J/m² UV-C, or 1 mM HU) and
650 subsequently cultured for the indicated time. The cells were pulse-labeled with 10 µM EdU for 30 min
651 before harvesting. The cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining
652 Buffer Set (Thermo Fisher Scientific; 00-5523-00) following the manufacturer's protocol. EdU staining
653 was performed by incubating the cells with the Click-iT reaction cocktail, prepared as per
654 manufacturer's instructions. The cells were stained with permeabilization buffer containing anti-
655 γH2AX-AF488 (S139) (2F3; BioLegend; 613406) for 30 min on ice when indicated. DNA content was
656 stained using permeabilization buffer containing DAPI. Acquisition of the stained cells was performed
657 using a BD LSRFortessa or BD FACSymphony A3 (BD Biosciences). Subsequent data analysis was
658 performed with the FlowJo v10.10.0 software (BD Life Sciences).

659 *EdU pulse-chase assay.* The EdU pulse-chase assay was performed as previously described by Duthoo
660 et al.⁶⁰, with minor adjustments. Briefly, PHA blasts were cultured for 96h in a 48-well plate (250,000
661 cells in 500 µl) in the presence of 2% PHA-M. Next, the cells were pulse-labeled with 10 µM EdU for
662 30 min and concurrently exposed to a DNA damage inducer (200 J/m² UV-C or 4 Gy IR). MMC (0.02
663 µg/ml) was added to the culture 24h prior to EdU labeling. Subsequent harvesting of the cells was
664 performed at various time points, ranging from 0 to 15h, with intervals of 3h. The cells were fixed and
665 permeabilized using the Foxp3 / Transcription Factor Staining Buffer Set. Subsequent EdU staining was
666 performed using the Click-iT reaction cocktail and DNA was stained with permeabilization buffer
667 containing DAPI. Acquisition was performed using a BD LSRFortessa (BD Biosciences) and data was
668 analyzed with the FlowJo software.

669 *Proliferation assay.* Cryopreserved PBMCs were resuspended in PBS at a density of 1 × 10⁶ cells per
670 ml. Cells were labeled with CellTrace Violet (CTV) (1 µM; Thermo Fisher Scientific; C34557) and
671 incubated for 10 min at 37°C. Unbound CTV was quenched by washing the cells with PBS
672 supplemented with 1% FCS. The cells were seeded in a 48-well plate (250,000 cells in 500 µl), treated

673 with 0.02 µg/ml MMC, and subsequently stimulated with 2% PHA-M. After 96h of culture, PHA blasts
674 were harvested and stained with anti-CD3-AF700 (SK7; BioLegend; 344822), anti-CD4-FITC (RPA-
675 T4; BD Bioscience; 561005), anti-CD8-PE-Cy7 (RPA-T8; BD Bioscience; 557746), and FcR block
676 (BioLegend; 422302) in PBS. After 30 min of staining, cells were washed, stained with propidium iodide
677 (PI), and acquired using a BD LSRFortessa (BD Biosciences). Subsequent data analysis was performed
678 with the FlowJo software.

679 *Immunophenotyping.* Cryopreserved PBMCs were thawed in 37°C preheated complete medium (RPMI-
680 1640 medium supplemented with GlutaMAX, 10% FCS, 1% penicillin-streptomycin (Pen/Strep)
681 (10,000 U/mL; Gibco; 15140122), 1 mM sodium pyruvate (Gibco; 11360070), 1% non-essential amino
682 acids (NEAA) (Gibco; 11140035), and 50 µM 2-mercaptoethanol (Gibco; 31350010)). Cells were left
683 to recuperate for 30 min at 37°C and 5% CO₂ after removal of DMSO. Cells were counted and
684 2,000,000 cells were plated for each panel. Cells were first stained with FcR block (BioLegend; 422302)
685 together with biotin conjugated antibodies and Zombie UV™ Fixable Viability dye (BioLegend;
686 423107) in PBS. In a second step, a first set of surface markers were stained with a mixture of antibodies
687 in FACS buffer (DPBS pH7.4, 1% Bovine Serum Albumin, 0.05% NaN₃, 1 mM EDTA) and Brilliant
688 Stain buffer (BD Biosciences). After 30 min of staining, cells were washed and stained overnight with
689 a second set of antibodies. Cells were fixed, permeabilized, and intracellular stained with antibodies
690 using the Foxp3/Transcription Factor Staining Buffer Set according to the manufacturer's protocol.
691 Acquisition and analysis of labeled cell suspensions was performed with a FACSymphony flow
692 cytometer (BD biosciences) and subsequent analysis of data with the FlowJo software. Antibodies used
693 to define PBMC populations can be found in Supplementary Table 6.

694 **Single-cell RNA, TCR, BCR, and CITE sequencing**

695 After thawing, up to 2x10⁶ PBMCs of each individual were counted, isolated, and spun down. The cell
696 pellet was resuspended and incubated for 30 min on ice with staining mix in PBS containing 0.04%
697 BSA, CD19-PE-Cy7, eFluor506 Fixable Viability dye, Human TruStain FcX (BioLegend; 422302), and
698 TotalSeq-C hashing antibodies (1:500; BioLegend). Two patient samples were multiplexed per lane
699 using TotalSeq-C Cell Hashing Antibodies. Both total live PBMCs and B cells were sorted and loaded
700 on different lanes. Sorted single-cell suspensions were resuspended at an estimated final concentration
701 of 2,000 cells/µl and loaded on a Chromium GemCode Single Cell Instrument (10x Genomics) to
702 generate single-cell gel beads in emulsion. The scRNA/Feature Barcoding/TCR libraries were prepared
703 using the GemCode Single Cell 5' Gel Bead and Library kit, version 1.1 (10x Genomics; 1000165),
704 according to the manufacturer's instructions. The cDNA content of prefragmentation and post-sample
705 index PCR samples was analyzed using the 2100 BioAnalyzer (Agilent). Sequencing libraries were
706 loaded on an Illumina NovaSeq flow cell at Vlaams Instituut voor Biotechnologie (VIB) Nucleomics
707 core with sequencing settings according to the recommendations of 10x Genomics, pooled in a 75:20:5
708 ratio for the gene expression, TCR, and antibody-derived libraries, respectively.

709 **LAM-HTGTS**

710 To study CSR patterns in B cells from F1Pt and healthy controls, a modified version of the linear
711 amplification-mediated high-throughput genome-wide translocation sequencing (LAM-HTGTS)
712 method was used, as described in Takada et al.⁴⁹.

713 **Cytotoxicity assay**

714 Fibroblasts were seeded into 24-well plates at a density of 6,000 cells/cm² 24h before starting the
715 experiment. Cells were exposed to a DNA damage inducer (0.2 µg/ml MMC, 20 J/m² UV-C or 10 Gy
716 IR) and incubated with SYTOX Green nucleic acid stain (1:100000; Invitrogen) to indicate dead cells

717 during cell culture. Brightfield and fluorescence images were captured for 5 days with an 8h interval
718 with the CELLCYTE X (Cytena). Cell confluency and the number of dead cells were quantified using
719 CELLCYTE X Analysis software.

720 **CRISPR-Select^{TIME} in mono-allelic cell system**

721 *Generation of mono-allelic ATR^{+/-} and ATRIP^{+/-} cell lines.* An iCas9-MCF10A-WT clonal cell line with
722 stably integrated TRE3G Edit-R Inducible Lentiviral Cas9 construct (Horizon; CAS11229) was gifted
723 by Roderick L. Beijersbergen, The Netherlands Cancer Institute. To generate ATR^{+/-} cells, iCas9-
724 MCF10A-WT cells were transfected with dual gRNAs targeting intron 1 and intron 46 of the *ATR* gene.
725 ATRIP^{+/-} cells were generated by transfecting the iCas9-MCF10A-WT cells with dual gRNAs targeting
726 intron 1 and intron 8 of the *ATRIP* gene. Two CRISPR RNAs (crRNAs) for *Streptococcus pyogenes*
727 Cas9 were designed using the online software Crispor (<http://crispor.tefor.net/crispor.py>). Note, the
728 crRNAs should be located in the non-coding region to avoid disturbing adjacent genes. The knock-out
729 efficiency of the designed crRNAs was analyzed by the online tool ICE (<https://ice.synthego.com/#/>),
730 and subsequently, the crRNAs with a high knock-out efficiency were selected to establish the mono-
731 allelic cell line. The iCas9-MCF10A-WT cells were seeded with 60% confluency in a 6 cm culture dish.
732 To induce the expression of the cas9 protein, 1 µg/ml doxycycline was added to the medium. After 24h,
733 7.5 µl of each crRNA (2 nmol) was mixed with 15 µl of trans-activating crRNA (tracrRNA, 5 nmol)
734 and was incubated at room temperature for 10 min to form crRNA:tracrRNA duplexes. Cells were
735 subsequently transfected by 4 ml of culture medium containing 30 µl crRNA:tracrRNA duplexes, 15 µl
736 lipofectamine RNAiMAX (Thermo Fisher Scientific; 13778), and 500 µl Opti-MEM (Thermo Fisher
737 Scientific; 31985062). After 2 days of culture, single cells were sorted into 96-well plates with 100 µl
738 fresh medium per well using a FACS Aria III instrument (BD Biosciences) and subsequently kept in
739 culture 2-3 weeks until clonal cell lines were formed. Genomic PCR was performed to evaluate the
740 mono-allelic cell line. Primers targeting WT, *ATR*, or *ATRIP* deletion alleles were designed through
741 Primer3 (<https://primer3.ut.ee/>). Primers annealing to sequences outside the depletion region were used
742 to identify the knock-out alleles. Primers annealing to sequences inside the deleted regions were used to
743 detect the WT allele. The cell colonies containing DNA that is successfully amplified by both two types
744 of primers were mono-allelic cell lines. DNA extraction was performed using the Quick-DNATM
745 Miniprep Plus Kit (Zymo Research; D4069). PCR was performed using 100 ng genomic DNA and 1%
746 agarose gel electrophoreses. For further verification, the PCR products of target sites were purified using
747 the QIAquick Gel Extraction Kit (QIAGEN; 28706) and were sent to Eurofins for Sanger sequencing.
748 The designed crRNAs and PCR primers are listed in Supplementary Table 7.

749 *In vitro CRISPR-Select^{TIME} assay.* In a 6-well plate, 17,500 iCas9-MCF10A-ATR^{+/-} or ATRIP^{+/-} cells
750 were seeded in 2 ml culture medium per well. To induce the expression of Cas9 protein, 1 µg/ml
751 doxycycline was added in each well 24h before cell transfection. After 24h, 7.5 µl of the designed
752 crRNA (2 nmol) was incubated for 10 min at room temperature with 7.5 µl of tracrRNA (5nmol). Next,
753 a mixture of 15 µl crRNA:tracrRNA duplexes, 7.5 µl lipofectamine RNAiMAX, 250 µl Opti-MEM, and
754 2 µl mixture of designed variant (10 µM) and WT* single-stranded oligodeoxynucleotide (ssODN)
755 repair templates was dripped onto the iCas9-MCF10A cells in fresh medium. The DNA repair template
756 for each variant was designed in the online software Benchling (<https://benchling.com>). The design of
757 the synonymous mutations referring to the codon usage information were posted on
758 <https://www.kazusa.or.jp>. After 2 days, 50% of the edited cells were collected and DNA extraction was
759 performed using the Quick-DNATM Miniprep Plus Kit. The remaining edited cells were kept in culture
760 and passaged every 3 days. After an additional 10 days of culture, all cells were collected and lysed for
761 DNA extraction using the Quick-DNATM Miniprep Plus Kit. Using Benchling and Primer3, PCR primers
762 for the amplification of the edited target sites in each variant were designed. Two rounds of PCR were

763 performed to prepare the PCR products for subsequent amplicon NGS. Firstly, primer pairs were used
764 to amplify the specific edited target sites, containing overhangs with binding sites for the primers of the
765 second round. Secondly, specific barcodes were added to each sample, including overhangs with
766 barcodes or adaptors for NGS. After purifying the PCR products using the QIAquick Gel Extraction Kit,
767 NGS was performed to sequence the PCR products of the DNA samples collected on day 2 and day 12.
768 The ratio of read numbers of the knock-in of a variant relative to the WT* on day 2 and day 12 were
769 compared to determine the functional characteristics of the different mutations. The designed crRNAs,
770 PCR primers, and DNA repair templates are listed in Supplementary Table 8 and 9.

771 **Statistical analyses**

772 GraphPad Prism software (version 10) was used for all statistical analyses. As indicated in the figure
773 legends, results were analyzed with a two-tailed Mann-Whitney test, multiple paired t-tests, or Kruskal-
774 Wallis test combined with Dunn's multiple comparisons test. The threshold for statistical significance
775 was set to $p < 0.05$. Representative immunofluorescence images and flow cytometric plots are shown. R
776 (v4.3.2) and RStudio (v2023.09.1+494) were used for analysis of scRNA, TCR, BCR, and CITE
777 sequencing data. The analytical pipeline consisted of Cellranger (v6.1.1) for quality control. CITE-seq
778 and scRNA-seq data were analyzed using Seurat package (v5), with an embedded Presto package
779 (v1.0.0) for differential gene expression analysis. Analysis of TCR-seq and BCR-seq data was conducted
780 using the Diversity AnaLysis Interface (DALI, v2.0.0).

781 **Supplementary Materials**

782 Case descriptions

783 Supplementary figures 1-8

784 Supplementary tables 1-9

785

786 **References:**

- 787 1. Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA
788 Damage Response. *Mol Cell* **66**, 801–817 (2017).
- 789 2. Ciccia, A. & Elledge, S. J. The DNA Damage Response: Making It Safe to Play with Knives. *Mol*
790 *Cell* **40**, 179–204 (2010).
- 791 3. Cimprich, K. A. & Cortez, D. ATR: An essential regulator of genome integrity. *Nat Rev Mol Cell*
792 *Biol* **9**, 616–627 (2008).
- 793 4. Matsuoka, S. *et al.* ATM and ATR Substrate Analysis Reveals Extensive Protein Networks
794 Responsive to DNA Damage. *Science (1979)* **316**, 1160–1166 (2007).
- 795 5. Jazayeri, A. *et al.* ATM- and cell cycle-dependent regulation of ATR in response to DNA double-
796 strand breaks. *Nat Cell Biol* **8**, 37–45 (2006).
- 797 6. Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: Ensuring faithful duplication
798 of a challenging genome. *Nat Rev Mol Cell Biol* **18**, 622–636 (2017).
- 799 7. Klein, A. De *et al.* Targeted disruption of the cell-cycle checkpoint gene ATR leads to early
800 embryonic lethality in mice. *Current Biology* **10**, 479–482 (2000).
- 801 8. Brown, E. J. & Baltimore, D. ATR disruption leads to chromosomal fragmentation and early
802 embryonic lethality. *Genes Dev* **14**, 397–402 (2000).
- 803 9. Nam, E. A., Zhao, R. & Cortez, D. Analysis of mutations that dissociate G 2 and essential S phase
804 functions of human Ataxia Telangiectasia-mutated and Rad3-related (ATR) protein kinase. *Journal*
805 *of Biological Chemistry* **286**, 37320–37327 (2011).
- 806 10. Lam, F. C. The DNA damage response - from cell biology to human disease. *J Transl Genet Genom*
807 **6**, 204–222 (2022).
- 808 11. Cortez, D., Guntuku, S., Qin, J. & Elledge, S. J. ATR and ATRIP: Partners in Checkpoint Signaling.
809 *Science (1979)* **294**, 1713–1716 (2001).
- 810 12. O’Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation
811 affecting expression of ataxia – telangiectasia and Rad3 – related protein (ATR) results in Seckel
812 syndrome. *Nat Genet* **33**, 497–501 (2003).
- 813 13. Goodship, J. *et al.* Autozygosity Mapping of a Seckel Syndrome Locus to Chromosome 3q22.1-q24.
814 *Am. J. Hum. Genet* **67**, 498–503 (2000).
- 815 14. Ogi, T. *et al.* Identification of the First ATRIP – Deficient Patient and Novel Mutations in ATR
816 Define a Clinical Spectrum for ATR – ATRIP Seckel Syndrome. *PLoS Genet* **8**, (2012).
- 817 15. Mokrani-Benhelli, H. *et al.* Primary Microcephaly, Impaired DNA Replication, and Genomic
818 Instability Caused by Compound Heterozygous ATR Mutations. *Hum Mutat* **34**, 374–384 (2013).
- 819 16. Llorens-Agost, M. *et al.* Analysis of novel missense ATR mutations reveals new splicing defects
820 underlying Seckel syndrome. *Hum Mutat* **39**, 1847–1853 (2018).
- 821 17. Bass, T. E. *et al.* ETAA1 acts at stalled replication forks to maintain genome integrity. *Nat Cell Biol*
822 **18**, 1185–1195 (2016).
- 823 18. Wang, X. *et al.* 3.9 Å structure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP.
824 *Structural Biology* **358**, 1206–1209 (2017).
- 825 19. Deshpande, I. *et al.* Structural Basis of Mec1-Ddc2-RPA Assembly and Activation on Single-
826 Stranded DNA at Sites of Damage. *Mol Cell* **68**, 431–445.e5 (2017).
- 827 20. Rao, Q. *et al.* Cryo-EM structure of human ATR-ATRIP complex. *Cell Res* **28**, 143–156 (2018).
- 828 21. Delacroix, S., Wagner, J. M., Kobayashi, M., Yamamoto, K. I. & Karnitz, L. M. The Rad9-Hus1-
829 Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. *Genes Dev* **21**, 1472–1477 (2007).
- 830 22. Haahr, P. *et al.* Activation of the ATR kinase by the RPA-binding protein ETAA1. *Nat Cell Biol* **18**,
831 1196–1207 (2016).

- 832 23. Cybulski, C. *et al.* Variants in ATRIP are associated with breast cancer susceptibility in the Polish
833 population and UK Biobank. *Am J Hum Genet* **110**, 648–662 (2023).
- 834 24. Matos-Rodrigues, G. E. *et al.* ATRIP protects progenitor cells against DNA damage in vivo. *Cell*
835 *Death Dis* **11**, (2020).
- 836 25. Klingseisen, A. & Jackson, A. P. Mechanisms and pathways of growth failure in primordial dwarfism.
837 *Genes Dev* **25**, 2011–2024 (2011).
- 838 26. Reynolds, J. J. *et al.* Mutations in DONSON disrupt replication fork stability and cause microcephalic
839 dwarfism. *Nat Genet* **49**, 537–549 (2017).
- 840 27. Harley, M. E. *et al.* TRAIP promotes DNA damage response during genome replication and is
841 mutated in primordial dwarfism. *Nat Genet* **48**, 36–43 (2015).
- 842 28. Khetarpal, P., Das, S., Panigrahi, I. & Munshi, A. Primordial dwarfism: overview of clinical and
843 genetic aspects. *Molecular Genetics and Genomics* **291**, 1–15 (2016).
- 844 29. Conde, C. D. *et al.* Polymerase δ deficiency causes syndromic immunodeficiency with replicative
845 stress. *Journal of Clinical Investigation* **129**, 4194–4206 (2019).
- 846 30. Conte, M. I. *et al.* Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with
847 neutropenia. *JCI Insight* **7**, (2022).
- 848 31. Cottineau, J. *et al.* Inherited GINS1 deficiency underlies growth retardation along with neutropenia
849 and NK cell deficiency. *Journal of Clinical Investigation* **127**, 1991–2006 (2017).
- 850 32. Cui, Y. *et al.* Combined immunodeficiency caused by a loss-of-function mutation in DNA
851 polymerase delta 1. *Journal of Allergy and Clinical Immunology* **145**, 391-401.e8 (2020).
- 852 33. Frugoni, F. *et al.* A novel mutation in the POLE2 gene causing combined immunodeficiency. *Journal*
853 *of Allergy and Clinical Immunology* **137**, 635-638.e1 (2016).
- 854 34. Gineau, L. *et al.* Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency,
855 and natural killer cell deficiency. *Journal of Clinical Investigation* **122**, 821–832 (2012).
- 856 35. Hughes, C. R. *et al.* MCM4 mutation causes adrenal failure, short stature, and natural killer cell
857 deficiency in humans. *Journal of Clinical Investigation* **122**, 814–820 (2012).
- 858 36. Nichols-Vinueza, D. X. *et al.* POLD1 Deficiency Reveals a Role for POLD1 in DNA Repair and T
859 and B Cell Development. *J Clin Immunol* **41**, 270–273 (2021).
- 860 37. Schmid, J. P. *et al.* Polymerase ϵ 1 mutation in a human syndrome with facial dysmorphism,
861 immunodeficiency, livedo, and short stature ('FILS syndrome'). *Journal of Experimental Medicine*
862 **209**, 2323–2330 (2012).
- 863 38. Niu, Y. *et al.* Multiparametric and accurate functional analysis of genetic sequence variants using
864 CRISPR-Select. *Nat Genet* **54**, 1983–1993 (2022).
- 865 39. Masih, S. *et al.* Deciphering the molecular landscape of microcephaly in 87 Indian families by exome
866 sequencing. *Eur J Med Genet* **65**, (2022).
- 867 40. Mordes, D. A., Glick, G. G., Zhao, R. & Cortez, D. TopBP1 activates ATR through ATRIP and a
868 PIKK regulatory domain. *Genes Dev* **22**, 1478–1489 (2008).
- 869 41. Ball, H. L., Myers, J. S. & Cortez, D. ATRIP Binding to Replication Protein A-Single-stranded DNA
870 Promotes ATR-ATRIP Localization but Is Dispensable for Chk1 Phosphorylation. *Mol Biol Cell* **16**,
871 2372–2381 (2005).
- 872 42. Namiki, Y. & Zou, L. ATRIP associates with replication protein A-coated ssDNA through multiple
873 interactions. *Proc Natl Acad Sci U S A* **103**, 580–585 (2006).
- 874 43. Itakura, E. *et al.* Amino-terminal domain of ATRIP contributes to intranuclear relocation of the ATR-
875 ATRIP complex following DNA damage. *FEBS Lett* **577**, 289–293 (2004).
- 876 44. Lee, Y. N. *et al.* Characterization of T and B cell repertoire diversity in patients with RAG deficiency.
877 *Sci Immunol* **1**, (2016).

- 878 45. Foth, S., Völkel, S., Bauersachs, D., Zemlin, M. & Skevaki, C. T Cell Repertoire During Ontogeny
879 and Characteristics in Inflammatory Disorders in Adults and Childhood. *Front Immunol* **11**, (2021).
- 880 46. Pan-Hammarström, Q. *et al.* Disparate roles of ATR and ATM in immunoglobulin class switch
881 recombination and somatic hypermutation. *Journal of Experimental Medicine* **203**, 99–110 (2006).
- 882 47. Sun, X. *et al.* ATR kinase activity promotes antibody class switch recombination in B cells through
883 cell cycle regulation without suppressing DSB resection and microhomology usage. *J Leukoc Biol*
884 **110**, 1101–1112 (2021).
- 885 48. Hu, J. *et al.* Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-
886 mediated high-throughput genome-wide translocation sequencing. *Nat Protoc* **11**, 853–871 (2016).
- 887 49. Takada, S. *et al.* Causative mechanisms and clinical impact of immunoglobulin deficiencies in ataxia
888 telangiectasia. *Journal of Allergy and Clinical Immunology* **153**, 1392–1405 (2024).
- 889 50. Saha, J., Wang, S. & Davis, A. J. Examining DNA double-strand break repair in a cell cycle
890 dependent manner. *Methods Enzymol* **591**, 97–118 (2017).
- 891 51. Liu, S. *et al.* ATR Autophosphorylation as a Molecular Switch for Checkpoint Activation. *Mol Cell*
892 **43**, 192–202 (2011).
- 893 52. Nam, E. A. *et al.* Thr-1989 phosphorylation is a marker of active ataxia telangiectasia- mutated and
894 Rad3-related (ATR) kinase. *Journal of Biological Chemistry* **286**, 28707–28714 (2011).
- 895 53. Lossaint, G. *et al.* Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to
896 mediate senescence onset after G2 arrest. *J Cell Sci* **135**, (2022).
- 897 54. Stiff, T. *et al.* ATR-dependent phosphorylation and activation of ATM in response to UV treatment
898 or replication fork stalling. *EMBO Journal* **25**, 5775–5782 (2006).
- 899 55. Hanasoge, S. & Ljungman, M. H2AX phosphorylation after UV irradiation is triggered by DNA
900 repair intermediates and is mediated by the ATR kinase. *Carcinogenesis* **28**, 2298–2304 (2007).
- 901 56. Toledo, L. I. *et al.* XATR prohibits replication catastrophe by preventing global exhaustion of RPA.
902 *Cell* **155**, 1088–1103 (2013).
- 903 57. Eklund, H., Uhlin, U., Arneg(Ardh, M. F., Logan, D. T. & Ar Nordlund, P. Structure and function
904 of the radical enzyme ribonucleotide reductase. *Prog Biophys Mol Biol* **77**, 177–268 (2001).
- 905 58. Cliby, W. A. *et al.* Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-
906 damaging agents and defects in cell cycle checkpoints. *EMBO J* **17**, 159–169 (1998).
- 907 59. Liu, Q. *et al.* Chk1 is an essential kinase that is regulated by Atr and required for the G 2 /M DNA
908 damage checkpoint. *Genes Dev* **14**, 1448–1459 (2000).
- 909 60. Duthoo, E., Vral, A. & Baeyens, A. An updated view into the cell cycle kinetics of human T
910 lymphocytes and the impact of irradiation. *Sci Rep* **12**, 1–12 (2022).
- 911 61. Murga, M. *et al.* A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated
912 aging. *Nat Genet* **41**, 891–898 (2009).
- 913 62. Jeon, Y. *et al.* TopBP1 deficiency causes an early embryonic lethality and induces cellular senescence
914 in primary cells. *Journal of Biological Chemistry* **286**, 5414–5422 (2011).
- 915 63. Zhou, Z. W. *et al.* An Essential Function for the ATR-Activation-Domain (AAD) of TopBP1 in
916 Mouse Development and Cellular Senescence. *PLoS Genet* **9**, (2013).
- 917 64. Shin, U. *et al.* Large-scale generation and phenotypic characterization of zebrafish CRISPR mutants
918 of DNA repair genes. *DNA Repair (Amst)* **107**, (2021).
- 919 65. Zou, L. & Elledge, S. J. Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA
920 Complexes. *Science (1979)* **300**, 1538–1542 (2003).
- 921 66. Murga, M. *et al.* A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated
922 aging. *Nat Genet* **41**, 891–898 (2009).
- 923 67. Ruzankina, Y. *et al.* Deletion of the Developmentally Essential Gene ATR in Adult Mice Leads to
924 Age-Related Phenotypes and Stem Cell Loss. *Cell Stem Cell* **1**, 113–126 (2007).

- 925 68. Schuler, F. *et al.* Checkpoint kinase 1 is essential for normal B cell development and
926 lymphomagenesis. *Nat Commun* **8**, (2017).
- 927 69. Schoeler, K. *et al.* CHK1 dosage in germinal center B cells controls humoral immunity. *Cell Death*
928 *Differ* **26**, 2551–2567 (2019).
- 929 70. Menolfi, D. *et al.* Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR
930 and RPA. *Nat Commun* **9**, 1–16 (2018).
- 931 71. Willemsen, M. *et al.* DNA replication–associated inborn errors of immunity. *Journal of Allergy and*
932 *Clinical Immunology* **151**, 345–360 (2023).
- 933 72. Guo, C. *et al.* XRCC4 deficiency in human subjects causes a marked neurological phenotype but no
934 overt immunodeficiency. *Journal of Allergy and Clinical Immunology* **136**, 1007–1017 (2015).
- 935 73. Butler, M. G., Hall, B. D., Maclean, R. N. & Lozzio, C. B. Do some patients with Seckel syndrome
936 have hematological problems and/or chromosome breakage? *Am J Med Genet* **27**, 645–649 (1987).
- 937 74. Woods, C. G., Leversha, M. & Rogers, J. G. Severe intrauterine growth retardation with increased
938 mitomycin C sensitivity: A further chromosome breakage syndrome. *J Med Genet* **32**, 301–305
939 (1995).
- 940 75. Arnold, S. R., Spicer, D., Kouseff, B., Lacson, A. & Gilbert-Barness, E. Seckel-like syndrome in
941 three siblings. *Pediatric and Developmental Pathology* **2**, 180–187 (1999).
- 942 76. Hayani, A., Suarez, C. R., Molnar, Z., LeBeau, M. & Godwin, J. Acute myeloid leukaemia in a patient
943 with Seckel syndrome. *J Med Genet* **31**, 148–149 (1994).
- 944 77. Majewski, F. & Goecke, T. Studies of microcephalic primordial dwarfism I: Approach to a
945 delineation of the Seckel syndrome. *Am J Med Genet* **12**, 7–21 (1982).
- 946 78. Thompson, E. & Pembrey, M. Seckel syndrome: An overdiagnosed syndrome. *J Med Genet* **22**, 192–
947 201 (1985).
- 948 79. Nykamp, K. *et al.* Sherloc: a comprehensive refinement of the ACMG-AMP variant classification
949 criteria. *Genet Med* **19**, 1105–1117 (2017).
- 950 80. Beyls, E., Baeyens, A. & Vral, A. The cytokinesis-block micronucleus assay for cryopreserved whole
951 blood. *Int J Radiat Biol* **97**, 1252–1260 (2021).
- 952 81. Francies, F. Z. *et al.* Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced
953 micronuclei. *DNA Repair (Amst)* **61**, 17–24 (2018).
- 954 82. Fenech, M. Cytokinesis-block micronucleus cytome assay. *Nat Protoc* **2**, 1084–1104 (2007).
- 955
- 956

957 **Statements**

958 Personally identifiable patient information was redacted in accordance with medRxiv requirements. IDs
959 used in this study were not known to anyone outside the research group, unless they were previously
960 published and are thus part of the public domain (PMID23144622 and PMID35568357).

961 **Acknowledgments**

962 We gratefully thank the patients and family for consenting to this research. The valuable input from
963 prof. Penny Jeggo, prof. Grant Stewart, prof. Mark O'Driscoll, Dr. Angela Brady, Dr. Mohnish Suri,
964 Dr. Pradeep Vasudevan, Dr. Emma Hobson, Dr. Kaljit Bhuller, and Dr. Mandal Kausik on the clinical
965 phenotype of the ATRIP and ATR patients is warmly appreciated. We thank Karlien Claes for the patient
966 centered support, Sylvie De Buck for the administrative assistance, Lieselotte Vande Walle and Sarah
967 Ghistelinck for the experimental expertise, and Julie Smet for providing NK cytotoxicity data. We
968 acknowledge the VIB Flow Core and VIB Single Cell Core of the VIB center for inflammation research
969 for their assistance and expertise in experimental design.

970 **Funding**

971 This work is supported (not financially) by the European Reference Network for Rare
972 Immunodeficiency, Autoinflammatory, and Autoimmune Diseases Network (ERN-RITA). This work
973 was funded by Research Foundation Flanders (FWO) (FWOTBM2018000102) and VIB Grand
974 Challenge. Simon Tavernier is a beneficiary of a senior postdoctoral FWO grant (1236923N). Sebastian
975 Riemann is funded by Ghent University (BOF23/DOC/013). Centre for Primary Immune deficiency
976 Ghent (CPIG) is recognized as Jeffrey Modell Diagnostic and Research center and funded by JMF
977 foundation.

978 **Author contributions**

979 Conceptualization: ED, EB, LB, TG, AB, AV, CSS, QPH, FH, KBMC, SJT
980 Methodology: ED, EB, LB, TG, AB, AV, CSS, QPH, FH, KBMC, SJT
981 Investigation: ED, EB, LB, PH, LJ, SR, BP, LD, VDB, MDB, JS, SJT
982 Clinical data collection: LH, TK, GM, FH
983 Visualization: ED, EB, LB, SJT
984 Funding acquisition: SR, EVB, AV, AB, FH, KBMC, SJT
985 Project administration: ED, EB, LB, SJT
986 Supervision: FH, KBMC, SJT
987 Writing – original draft: LB, ED, EB, SJT
988 Writing – review & editing: All authors

989 **Competing interests**

990 The authors declare that they have no competing interests.


991 **Data availability**

992 Code for scRNA-seq data analysis will be made available on GitHub upon publication. The plasmids
993 will be made available via GeneCorner upon publication (<https://bccm.belspo.be/genecorner>). The
994 *ATRIP* variant will be submitted to ClinVar and the Leiden Open Variation Database (LOVD) upon
995 publication.

996 **Materials & Correspondence**

997 Correspondence and requests for materials should be addressed to Filomeen Haerynck and Kathleen
998 Claes.

999 **Figures and Tables**




1000

1001 **Figure 1. Identification of homozygous complete loss-of-function ATRIP variants in patients with MPD.**

1002 **a** Family pedigree with allele segregation of *ATRIP* splice variant. Index patient (F1Pt) is marked with an arrow
 1003 and clinical phenotype and genotype is indicated in the legend. A detailed phenotypical description can be found
 1004 in Supplementary Materials. **b** Fragment analysis and size profiles of PCR-amplified cDNA extracted from PHA
 1005 blasts for F1Pt, parents (F1Fa and F1Mo), and a healthy control (HC). Arrows indicate the position of forward and
 1006 reverse primers used for PCR amplification. Percentages represent relative quantification of the 538bp wild type
 1007 and 380bp mutant (r.671_829del) fragment. Data is representative of five independent experiments. **c**
 1008 Electropherograms of cDNA extracted from PHA blasts of F1Pt and a control. Nucleotide numbering is in
 1009 accordance with ENST00000320211.1. Depicted profiles are reflective of five independent experiments. **d**
 1010 Schematic illustration of biallelic *ATRIP* variant effect at both transcript and amino acid level. **e** Endogenous
 1011 protein expression of ATRIP and complex partners in primary fibroblasts from F1Pt, father (F1Fa), and controls
 1012 (HCs). B-tubulin was used as loading control. Western blot image is reflective of four independent experiments. **f**
 1013 Peak size profile in base pairs (bp) of PCR-amplified cDNA extracted from EBV immortalized lymphoblastoid


1014 cell lines (EBV-LCLs) generated from the father (F1Fa) treated with and without puromycin. Percentages represent
1015 relative ratio of wild type (835bp) and mutant (380bp) fragments. Data is reflective of two independent
1016 experiments. **g** Schematic overview of the effect of the biallelic *ATRIP* variant at the protein level and an overview
1017 of the ATR-ATRIP complex with downstream effector CHK1. **h** HEK293T cells were transiently co-transfected
1018 with 3xFLAG-tagged ATRIP (3xFLAG-wtATRIP or 3xFLAG-mutATRIP), RPA70-Myc, and ATR-V5. After
1019 immunoprecipitation with anti-FLAG or control IgG, interaction between ATRIP (FLAG) and ATR (V5), RPA70
1020 (Myc), and endogenous TOPBP1 was examined by western blot analysis. B-tubulin serves as a loading control.
1021 Results are reflective of three independent experiments. Source data are provided as a Source Data file.



1022

1023 **Figure 2. Loss of ATRIP is associated with an immune deficiency, characterized by CD4⁺ T cell lymphopenia**
 1024 **and reduced B and CD16⁺ NK lymphocytes.**

1025 **a** Total numbers (No) of CD4⁺ T, CD8⁺ T, NK, and B cells in the peripheral blood from the ATRIP patient (F1Pt)
1026 over time. Shading indicates the age-based reference range. **b** Flow cytometric (FCM) immunophenotyping of
1027 F1Pt, family members, and age-matched healthy controls (HCs). Percentages of CD4⁺ T, CD8⁺ T, NK, and B cells
1028 in PBMCs from F1Pt, sister (F1Si), mother (F1Mo), and father (F1Fa). Data represents one experiment, with each
1029 datapoint representing one biological replicate. Mean and SEM are shown. **c** IgG2 concentration (Conc.) in the
1030 peripheral blood from F1Pt over time. Shading indicates the age-based reference range. Immunoglobulin
1031 substitution therapy is indicated. **d** Total numbers (No) of neutrophils in the peripheral blood from F1Pt,
1032 demonstrating intermittent neutropenia. Shading indicates the age-based reference range. **e** Hemoglobin
1033 concentration (Conc.) in the peripheral blood from F1Pt over time. Shading indicates age-based reference range.
1034 Corticosteroid (CORT) and anti-CD20 mAb treatment (aCD20) is indicated. **f** UMAP plot depicting cluster
1035 annotation of 25 unique T and NK subsets (left). Analysis was performed using concatenated 25-parameter FCM
1036 data of PBMCs obtained from HCs (n = 6) and F1Pt. Contour plots of HCs (middle, top) and F1Pt (middle, bottom).
1037 Bar graph showing the relative proportion of HCs and F1Pt within each T and NK subset cluster (right). **g** UMAP
1038 plot demonstrating cluster annotation of 18 unique B and innate subsets (left). Analysis was performed using
1039 concatenated 25-parameter FCM data of PBMCs obtained from HCs (n = 6) and F1Pt. Contour plots of HCs
1040 (middle, top) and F1Pt (middle, bottom). Bar graph depicting the relative contribution of HCs and F1Pt within
1041 each B and innate subset cluster (right). Data is representative of one experiment (f-i). Source data are provided as
1042 a Source Data file.




1043

1044 **Figure 3. TCR oligoclonality in CD8⁺ T_{EM} cells and altered class switch recombination (CSR) in absence of**
 1045 **ATRIP.**

1046 **a** CITE-seq profiling of PBMCs from healthy controls (HCs) (n =3) and ATRIP patient (F1Pt), identifying 25
 1047 immune subsets. UMAP visualization of pooled CITE-seq data of HCs and F1Pt, displaying the identified subsets
 1048 (left). UMAP plot of HCs (middle, top) and F1Pt (middle, bottom). Ratio of the 25 subsets in HCs and F1Pt, ranked
 1049 based on the prevalence in F1Pt (right). **b** Circos plots showing the *TRBV* and *TRAV* pairing pattern of CD8⁺ T
 1050 effector memory (T_{EM}) cells of healthy controls (HCs) and ATRIP patient (F1Pt). **c** Frequency of unique CD8⁺
 1051 T_{EM} cell clones in HCs and F1Pt. **d** Distribution of the CDR3 region lengths of TCR-α and TCR-β clones from
 1052 HCs and F1Pt CD8⁺ T_{EM} cells. **e** Frequency of class switch recombination junctions per S region in HCs (n = 3)
 1053 (junctions; n = 8305) and F1Pt (junctions; n = 2758). Mean and SD are shown. **f** Proportion of non-productive
 1054 junctions (inversional recombination) per S region in HCs (n = 3) (junctions; n = 652) and F1Pt (junctions; n =


1055 225). Mean and SD are shown. **g** Pie charts demonstrating the microhomology usage at S μ -S α junctions in HCs (n
1056 = 3) and F1Pt. Data represents one experiment (a-f). Source data are provided as a Source Data file.



1057

1058 **Figure 4. ATRIP deficiency presents with a DNA repair signature, interferon-driven immune dysregulation,**
1059 **and impaired T cell proliferation.**


1060 **a** Heatmap representing the top 10 enriched hallmark gene sets (MSigDB) in PBMCs of F1Pt compared to HCs
1061 (n = 3). **b** Volcano plot showing the differentially expressed genes in PBMCs of F1Pt compared to HCs (n = 3). **c**
1062 Heatmap displaying the serum concentration of the cytokines IL-10, IL-21, IL-18, IP-10, IL-6, IL-17A, IL-31,
1063 IFN γ , IL-27, MIP31, ICAM-1, IL-1RA, Eotaxin-3, IL-22, and IL-1 β in HCs (n = 13) and F1Pt pre- and post-
1064 treatment with anti-CD20 mAb. **d** CD169 and CD64 expression on CD14⁺ monocytes of HCs (n = 6) and F1Pt
1065 pre- and post-treatment with anti-CD20 mAb (aCD20). Histograms of a representative HC and F1Pt are shown.
1066 Bar plots depict median fluorescence (MFI). Mean and SEM are shown. **e** Lymphocyte transformation test (LTT)
1067 demonstrating the proliferative response of F1Pt whole blood to various stimuli. Data shows at least two
1068 independent analyses. **f** Proliferation analysis of CD8⁺ and CD4⁺ PHA blasts from HCs (n = 9) and F1Pt. PBMCs
1069 were labeled with CellTrace Violet (CTV) and stimulated with PHA for 96h. Precursor frequency (PF) and
1070 proliferation index (PI) of three independent experiments are depicted, with each datapoint representing one
1071 biological replicate. Mean and SD are shown. ns: not significant, *p<0.05, ***p<0.001, **** p<0.0001 (multiple
1072 unpaired t-tests). Source data are provided as a Source Data file.



1073

1074 **Figure 5. Absence of ATRIP does not abolish recruitment of ATR and its ability to phosphorylate substrates**
 1075 **but reveals an insufficient ATR signaling response.**

1076 **a** Fibroblasts from a healthy control (HC), ATRIP patient (F1Pt) and ATR patient (F02-98) were left untreated or
 1077 exposed to 0.02 µg/ml Mitomycin C (MMC), 200 J/m² UV or 2 Gy IR. ATR was stained by immunofluorescence
 1078 after 24h (MMC) or 3h (UV and IR) after exposure and ATR nuclear foci were quantified. Dot plot represents
 1079 pooled data from three independent experiments; at least 150 cells were analyzed for each condition. The median
 1080 number of foci is depicted. ns: not significant, **p<0.01, ***p<0.001, ****p<0.0001 (Kruskal-Wallis test and
 1081 Dunn's multiple comparisons test). **b** Protein expression of phosphorylation events (T1989-pATR, S317-pCHK1)
 1082 and total protein (ATR, CHK1) 3h post 200 J/m² UV radiation. Immunoblotting was performed on fibroblasts
 1083 from F1Pt, F02-98, and HCs (n = 3). Western blot is representative of three independent experiments. GAPDH
 1084 serves as a loading control. **c** pATR and pCHK1 levels shown in 2B were quantified. Bar graph depicts pATR and
 1085 pCHK1 levels post UV treatment, expressed as a fold increase over the levels observed in the Mock condition.
 1086 Mean and SD are shown. **d** Quantification of γH2AX nuclear fluorescence in HC and F1Pt fibroblasts 3h after 200
 1087 J/m² UV exposure and concomitant EdU pulse-labeling. The mean γH2AX intensity per nucleus is shown for
 1088 EdU- and EdU+ fibroblasts. Dot plot represents pooled data from three independent experiments. At least 200
 1089 (EdU-) or 90 (EdU+) cells were analyzed per condition. The median value is depicted. ns: not significant,
 1090 ****p<0.0001 (multiple Mann-Whitney tests and Bonferroni-Dunn multiple comparisons test). Representative
 1091 immunofluorescence images with DAPI, EdU, and γH2AX staining is shown (left). White arrows indicate EdU-
 1092 cells. Scale bars are 20 µm. **e** γH2AX expression was determined by flow cytometric analysis 3h following 200
 1093 J/m² UV exposure in EdU- (G0/G1 and G2/M phase) fibroblasts of HC and F1Pt. Median fluorescence intensity
 1094 (MFI) of γH2AX (AF488) is annotated on the histogram. Data are reflective of one experiment. Source data are
 1095 provided as a Source Data file.




1096

1097 **Figure 6. Loss of ATRIP results in compromised DNA replication and impaired cell cycle progression**
 1098 **following replication stress.**

1099 **a** Schematic outlining the treatment protocol of the flow cytometric (FCM) assay used in **b** and **c**. **b** Cell cycle
 1100 distributions of untreated fibroblasts from a healthy control (HC) and ATRIP patient (F1Pt). Representative FCM

1101 plots are shown (left). Scatter dot plot depicts data from eight independent experiments (right). Mean and SD are
1102 shown. ns: not significant (multiple paired t-tests). **c** FCM EdU pulse-labeling profiles of Mitomycin C (MMC)
1103 treated HC and F1Pt fibroblasts (top). Cells were exposed to 0.02 $\mu\text{g/ml}$ MMC for 24h in the absence or presence
1104 of an ATR kinase inhibitor (ATRi, 20 nM). Histograms of EdU and DAPI intensity in S phase cells are shown
1105 (bottom). The median fluorescence intensity (MFI) is annotated on the histogram. Data is representative of three
1106 independent experiments. **d** Quantification of RPA nuclear fluorescence in HC and F1Pt fibroblasts 3h after 1 mM
1107 Hydroxyurea (HU) exposure and concomitant EdU pulse-labeling. The mean RPA intensity per nucleus is shown
1108 for EdU+ cells. Dot plot represents data from pooled data from three experiments. The median value is depicted.
1109 ns: not significant; *** $p < 0.001$ (multiple Mann-Whitney tests and Bonferroni-Dunn multiple comparisons test). **e**
1110 FCM EdU pulse-labeling profiles of HC and F1Pt fibroblasts after the release from HU treatment (left). Cells were
1111 exposed to 1 mM HU for 3h, released for 3h, and subsequently harvested. Histograms of EdU intensity in S phase
1112 cells are shown (right). Data are representative of two experiments. **f** Cell cycle profiles of HC and F1Pt fibroblasts
1113 following 72h of 0.02 $\mu\text{g/ml}$ MMC treatment, with and without 20 nM ATRi. The percentage of cells in G2/M
1114 phase is indicated. Data is representative of three independent experiments. **g** EdU pulse-chase kinetics of HC and
1115 F1Pt PHA blasts. Cells were untreated or treated with genotoxic inducers (0.02 $\mu\text{g/ml}$ MMC or 200 J/m^2 UV),
1116 pulse-labeled with EdU, and harvested at indicated time points. Kinetic plots show percentages of EdU+ cells
1117 present in S phase (middle) and is representative of three independent experiments. **h** CellTrace Violet (CTV)
1118 profiles of CD8+ and CD4+ PHA blasts from HC and F1Pt after 96h of culture in the presence or absence of 0.02
1119 $\mu\text{g/ml}$ MMC. Data is representative of two experiment. Source data are provided as a Source Data file.




1120

1121

1122

Figure 7. Increased spontaneous DNA damage, chromosomal sensitivity, and impaired survival upon exposure to genotoxic inducers requiring ATR pathway activation in Seckel syndrome cells.

1123 **a** Immunofluorescence analysis of γ H2AX foci in untreated EdU- fibroblasts from a healthy control (HC), ATRIP
1124 patient (F1Pt), and ATR patient (F02-98). γ H2AX nuclear foci were quantified and are shown in a dot plot
1125 representing pooled data from three independent experiments. At least 150 cells were analyzed for each condition.
1126 The median number of foci is depicted. **** $p < 0.0001$ (Kruskall-Wallis test and Dunn's multiple comparisons
1127 test). **b** Schematic of principle and treatment protocols of the micronucleus (MN) assays depicted in c and d.
1128 Cytokinesis is blocked with cytochalasin B (CytoB), allowing scoring of MN in binucleate (BN) cells. **c, d** Using
1129 the G0 and S MN assay, micronuclei were scored in untreated PHA blasts (c) and in PHA blasts exposed to 1 Gy
1130 of ionizing radiation (IR) (d). The Mitomycin C (MMC) MN assay was used to quantify micronuclei in PHA blasts
1131 treated with 0.02 μ g/ml MMC (d). Mean MN values of a HC group are indicated by dashed lines. Dotted lines
1132 correspond to the mean+3SD and serve as a cut-off for sensitivity. Data of two independent experiments is shown
1133 for F1Pt, in each experiment an internal control (IC) was included. One experiment is performed for the family
1134 members (F1Si, F1Fa, F1Mo). **e** Bar graph depicts the total percentage of cell death after 120h of culture for
1135 untreated fibroblasts of HC, F1Pt, and F02-98. Mean and SD of at least three independent experiments is shown.
1136 **f** Schematic outlining of the treatment protocol of the cytotoxicity assay used in g and h. **g, h** Fibroblasts from HC,
1137 F1Pt, and F02-98 were untreated or exposed to genotoxic inducers (0.2 μ g/ml MMC, 20 J/m² UV, or 10 Gy IR)
1138 without (g) and with (h) kinase inhibitors (20 nM ATRi or 10 μ M ATMi) as indicated. Cell death was monitored
1139 by live imaging up to 120h by quantifying the number of cells stained with SYTOX Green. Cell death kinetics are
1140 reflective of at least two independent experiments. **i** Bar graph indicating % cell death after 120h of treatment for
1141 the experiments shown in g and h. Source data are provided as a Source Data file.



1142

1143 **Figure 8. Quantitative functional assay identifies fitness defect in genome engineered *ATRIP* c.829+5G>T**
 1144 **and *ATRIP* c.829+2T>G cells.**

1145 **a** Schematic representation of CRISPR-Select^{TIME} process for cell fitness testing. The depletion region of the *ATR*
 1146 and *ATRIP* genes are indicated. The CRISPR-Select cassettes for all the variants were transfected on day 2. Yellow
 1147 cross indicates the various editing outcomes on target gene. The cell samples from day 2 (D2) and day 12 (D12)
 1148 were collected and lysed for DNA extraction. PCR amplified the target edited sites of each sample and products
 1149 were analyzed by NGS sequencing. **b** Schematic illustration of the modeled compound heterozygous (hez) and
 1150 homozygous (hoz) *ATRIP* variants at the transcript level. **c** Cell fitness of MCF10A mono-allelic cells with the
 1151 *ATR* and *ATRIP* variants. Each symbol within the bar represents an independent experiment. Each variant has three
 1152 independent biological replicates. Mean and SEM are shown. Data of D12 is normalized to D2. **p<0.01,
 1153 ***p<0.0001, ns: non-significant (two-tailed paired t-tests). Source data are provided as a Source Data file.

1154 **Table 1. Full blood count and basic immunology screening of ATRIP patients (F1Pt and CV1720).** In case of F1Pt, the timepoints represent data prior to immunoglobulin
 1155 treatment (age 0-5y), pre anti-CD20 mAb treatment (age 16-20y), and post anti-CD20 mAb treatment (age 16-20y#). Blue and red bold text signify reduced and elevated values,
 1156 respectively, in comparison to age-matched reference values enclosed within brackets.

Immunological features	F1Pt			CV1720			
	0-5y	16-20y	16-20y#	6-10y	11-15y	11-15y	11-15y
Peripheral blood count							
White blood cell counts (/μl)	10830 (6000-15000)	1850 (4300-9640)	3060 (4300-9640)	5100 (5000-15500)	3200 (4500-13000)	3500 (4500-13000)	4500 (4500-13000)
Platelets (×10 ³ /mL)	311 (229-533)	87 (175-343)	194 (175-343)	279 (140-400)	218 (140-400)	199 (140-400)	190 (140-400)
Hemoglobin (g/dL)	12.1 (11.7-15.1)	7.4 (11.7-15.1)	13.4 (11.7-15.1)	13.9 (11.5-14.5)	14.0 (13.0-18.0)	16.0 (13.0-18.0)	15.0 (13.0-18.0)
Lymphocytes (/mL)	1191 (4000-10000)	1308 (1230-3420)	1050 (1230-3420)	1870 (1500-6500)	1430 (1500-6000)	1190 (1500-6000)	1830 (1500-6000)
Neutrophils (/mL)	7256 (1500-7500)	250 (1930-5780)	1280 (1930-5780)	2760 (1500-8000)	1410 (1800-8000)	1820 (1800-8000)	2090 (1800-8000)
Monocytes (/mL)	866 (400-1200)	117 (260-780)	410 (260-780)	350 (200-800)	230 (200-800)	420 (200-800)	330 (200-800)
Eosinophils (/mL)	106 (200-600)	161 (30-370)	260 (30-370)	100 (40-400)	70 (40-400)	70 (40-400)	180 (40-400)
Basophils (/mL)	217 (10-100)	0 (20-80)	40 (20-80)	40 (20-100)	30 (20-100)	0 (20-100)	20 (20-100)
Lymphocyte subsets							
T cells (CD3 ⁺) (/μL)	834 (900-4500)	1070 (700-2100)	1090 (700-2100)	N/A	N/A	N/A	1060 (1000-2200)
Helper T cells (CD4 ⁺) (/μL)	262 (500-2400)	551 (300-1400)	413 (300-1400)	N/A	N/A	N/A	710 (530-1300)
Cytotoxic T cells (CD8 ⁺) (/μL)	524 (300-1600)	492 (200-1200)	639 (200-1200)	N/A	N/A	N/A	277 (330-920)
B cells (CD19 ⁺) (/μL)	155 (200-2100)	139 (100-500)	16 (100-500)	N/A	N/A	N/A	480 (110-570)
NK cells (CD56 ⁺ /CD16 ⁺) (/μL)	N/A	58.9 (90-600)	53.5 (90-600)	N/A	N/A	N/A	150 (70-480)
Immunoglobulin levels							
IgM (g/L)	2.2 (0.27-0.63)	1.51 (0.4-2.48)	0.31 (0.4-2.48)#	N/A	N/A	N/A	N/A
IgA (g/L)	1.4 (0.5-1.24)	1.43 (0.71-3.65)	0.46 (0.71-3.65)#	N/A	N/A	N/A	N/A
Total IgG (g/L)	21.4 (4.7-9.3)	15.0 (7.0-16.0)	11.3 (7.0-16.0)	N/A	N/A	N/A	N/A
IgG2 (g/L)	0.28 (0.72-3.4)	1.79 (1.06-6.1)*	2.47 (1.5-6.4)*	N/A	N/A	N/A	N/A

1157 # after anti-CD20 mAb treatment, * under immunoglobulin replacement therapy.